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 N-glycosylation is one of the most abundant post-translational modifications in 
humans. N-glycans are processed in the ER and Golgi network by enzymes yielding 
heterogenous populations of N-glycosylation structures in vivo. N-glycosylation is part of 
the protein quality control and folding pathways. N-glycans also function in antigenicity, 
serum half-life, proteolysis protection, protein function and much more. N-glycosylation 
composition differences have been linked to disease states, age, gender, and 
pregnancy. These functionally relevant composition differences have also been taken 
advantage of by the pharmaceutical industry. 
Monoclonal antibody therapies (mAb) are estimated to exceed $140B in annual 
sales by 2024. mAb therapies function through direct binding of molecules in 
inflammation, neutralization or the complement cascade though the majority require 
FcR-mediated cell effector functions including antibody dependent cellular 
phagocytosis (ADCP) and antibody dependent cellular phagocytosis (ADCC). A second 
generation of glycoengineered monoclonal antibody (mAb) therapies have recently out-
performed their counterparts in clinical studies. This efficacy is thought to be directly 
related to the enhanced binding of antibody for FcRIII (CD16). CD16a is expressed 
predominantly on NK cells and monocytes and believed to be the main receptor 
engaged in ADCC. The role of the IgG antibody N-glycan has been well studied by 
others as well as previous members of the lab. However, the role of FcR N-
glycosylation including CD16a, CD16b and CD32a have not been well studied. Surface 
plasmon resonance (SPR) experiments designed to study the role of FcR N-
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glycosylation have shown less processed, oligomannose and hybrid-type N-glycans 
bind with higher affinity to IgG1 Fc than with complex-type N-glycans. CD16a expressed 
in a HEK293 Gnt1(-/-) cells give predominant Man5 N-glycosylation and bind 12-50 fold 
tighter than complex-type while CD16a with hybrid and oligomannose (Man9) bound 2-4 
fold tighter than complex-type. Interestingly, when all FcRs were expressed with Man5 
N-glycans instead of complex-type an enhanced affinity for IgG1 was observed on one 
FcR, CD16a, and is specific to one of five N-glycosylations sites, the N162 N-glycan.  
CD16b is a nearly identical paralogue to CD16a and differs by only four residues 
in the extracellular binding domains, thus it is a surprise that CD16b has a much weaker 
affinity for IgG1 and does not share an enhanced affinity when expressing Man5 as 
described with CD16a. A better understanding for this could lead to optimal mAb 
therapies. Interestingly only residue 129, a glycine in CD16a and aspartate in CD16b is 
the only residue of the four within the binding interface. CD16a G129D and CD16b 
D129G mutants expressing Man5 or complex-type N-glycans were subjected to SPR 
binding studies to IgG1 Fc. CD16b D129G bound with a 2-fold higher affinity than 
CD16a WT and a 90-fold higher affinity than CD16b WT. The reverse mutation in 
CD16a G129D, bound with a 128-fold decreased affinity to CD16a wt and comparable 
to CD16b WT. Furthermore, when comparing CD16 Man5 vs. complex-type N-glycans, 
the ‘lec effect’ was only observed in CD16a WT and CD16b D129G suggesting the 
interaction is more sensitive to CD16 N-glycosylation when G129 is present because 
when D129 was present there was a minimal difference between CD16 binding to IgG 
with a Man5 or complex-type N-glycan. An x-ray crystal structure of glycosylated CD16b 
in complex with afucosylated IgG1 Fc was determined to 2.2 Å resolution along with a 
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250 ns all-atom molecular dynamics simulation showed the D129 forces an unfavorable 
buckle in the CD16b backbone upon binding to IgG1 Fc. Furthermore, the D129 residue 
forces R155 to make different contacts with the N162 N-glycan. This may force the 
N162 N-glycan into different conformations which are less sensitive to N-glycan 
composition on CD16b as compared to CD16a. Overall, these results determine D129 
is responsible for the lower affinity of CD16b as compared to CD16a and this finding 
suggests mAb therapies could design antibodies to accommodate this residue.  
CD16a N-glycosylation composition affects binding to IgG1 in vitro. This finding 
lead our group to question whether immune response is modulated through CD16a N-
glycan composition in vivo. However, N-glycosylation composition of CD16a from 
endogenous tissue has not been elucidated before. Our lab developed methods to 
isolate CD16a from NK cells and monocytes from apheresis filters after platelet and 
plasma donations. Immunoprecipitation of CD16a typically yielded 1 to 2 g of CD16a 
from NK cells and 100 ng to 1 g from monocytes. A glycomics approach to CD16a 
from NK cells found higher oligomannose, less processed, material than what was 
found in recombinant sources. This study indicated recombinant CD16a glycoforms 
used by laboratories and the pharmaceutical industry do not recapitulate the material 
found in humans. A glycoproteomics approach was then used to identify composition of 
the 5 and 2 N-glycosylation sites of CD16a and CD32a from monocytes. CD16a at 
N162 was predominantly complex-type biantennerary, and some donors displayed up to 
20% of hybrid-types. N38 and N74 displayed highly processed, complex-type 
biantennerary. N169 displayed predominantly complex-type biantennerary with some 
highly processed complex-type. CD16a N45 was predominantly under processed with 
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mostly oligomannose and hybrid type. Interestingly, CD16a N45 from monocytes 
displays more oligomannose than from NK cells. CD16a from NK cells also displayed 
higher abundance of oligomannose and hybrid-types than CD16a from monocytes 
indicating higher affinity glycoforms on some NK cell donors. CD32a N64 and N145 
from monocytes displayed complex-type biantennerary with two sialic acids unlike any 
of the CD16a N-glycoyslation sites. Overall, N-glycosylation of CD16a appears to differ 
by cell-type, donor and site. These methods can now be used to expand donor 
populations and has the potential to characterize disease-relevant N-glycosylation 
differences as already has been elucidated in antibodies from populations with various 
disease states, gender and age.
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CHAPTER 1. INTRODUCTION. MULTIPLE VARIABLES AT THE LEUKOCYTE CELL 
SURFACE IMPACT FC  RECEPTOR-DEPENDENT MECHANISMS 
 
Portions of this chapter were published as a review in Frontiers in Immunology. DOI: 
10.3389/fimmu.2019.00223 
 
by Jacob T. Roberts, Kashyap R. Patel, Adam W. Barb 
 
Initials at the end of the subheading titles indicate contributions to that section 
 
Introduction: The importance of modulating the Fc-FcR interaction (KRP, JTR) 
Immunoglobulin G (IgG) is the most thoroughly studied and well characterized 
molecule of the humoral immune response. IgG activates the immune system through 
cell-bound Fc  Receptors (FcRs; Figure 1.1). The IgG fragment antigen-binding (Fab) 
domains confer specificity and affinity towards an antigen while the distinct hinge and 
fragment crystallizable (Fc) domain of the four IgG subclasses (IgG1-4) provide the 
structural basis for specificity and affinity to bind FcRs (1). The six structurally distinct 
members of the classical human FcRs (FcRI or CD64, FcRIIa / CD32a, FcRIIb / 
CD32b, FcRIIc / CD32c, FcRIIIa / CD16a and FcRIIIb / CD16b) are expressed on 
leukocytes of both the myeloid and lymphoid lineage. This group of proteins can be 
divided into two types: activating receptors (CD64, CD32a, CD32c, CD16a and CD16b) 
that lead to cell activation through immunoreceptor tyrosine-based activation motifs 
(ITAM) on cytosolic tails or on co-receptor molecules, and an inhibitory receptor 
(CD32b) that signals through immunoreceptor tyrosine-based inhibitory motifs (ITIM) (2-
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4). Only CD32s contain ITAM or ITIM domains, and the other receptors must associate 
with an ITAM-containing adaptor protein (FcRI  chain or CD3  chain) (3,5). In either 
situation, the ratio of activating to inhibiting signals determines the outcome of an 
immune response (6).  
Figure 1.1. Multiple variables affect FcR-mediated immune function (JTR, KRP). (A) Cellular 
variables influencing FcR activity that are present before the effector cell engages a target cell. (B) 
Cellular variables influencing FcR-mediated activity while the effector cell is engaged with a target cell.  
(C) Molecular variables associated with the FcRs, antibody and antigen.  
 
Receptor clustering is essential for FcR signaling. Circulating IgG coats an 
antigen to form an oligomeric complex, positioning the Fc portions of the IgG molecules 
away from the target surface and exposed to interact with FcRs. The antibody-coated 
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target is also referred to as an immune complex. The multiple IgG molecules of the 
immune complex provide an opportunity for multivalent interactions with FcR-
expressing leukocytes and must compete with non-complexed serum antibodies 
occupying the FcRs that will, in turn, cluster FcRs on the cell surface (7,8). Depending 
on the receptors engaged, the clustering of the extracellular domains triggers 
phosphorylation of tyrosine in the ITAMs or ITIMs, which subsequently recruits signaling 
molecules that promote a cellular response (9). The types of FcR-mediated effector cell 
responses are diverse and include, but are not limited to, antibody-dependent cellular 
cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), release of 
cytokines and antigen uptake for presentation (10-14). FcRs are critical for maintaining 
immune system homeostasis as well as preventing pathogenic infections and they play 
a major role in inflammatory diseases and autoimmune disorders (9,13,15-17). The 
combination of distinct antagonistic and synergistic factors contribute to a considerable 
functional diversity within this group of antibody receptors. In this chapter we will 
discuss multiple factors which influence the antibody:FcR interaction and modify the 
immune response with a focus on the role of N-glycosylation (Figure 1.1). 
 
Receptor presentation at the cell surface (JTR) 
FcRs are predominately expressed on cells originating from hematopoietic 
progenitor stem cells including dendritic cells, neutrophils, basophils, eosinophils, 
macrophages, monocytes, mast cells, NK cells, B cells, a subset of T cells, and 
platelets as well as non-hematopoietic cell types such as syncytiotrophoblasts at 
various levels (18-20). FcR expression varies depending on cell lineage; not 
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surprisingly gene copy number is also implicated in disease. These factors can greatly 
influence the dynamic ability of the immune system to respond to the diverse repertoire 
of foreign invaders. Thus, variable surface expression by different immune cell types 
influences how the immune system responds to a foreign invader. This section will 
cover the cellular expression of FcRs and immune modulation of expression through 
downregulation and induction. 
Five activating FcRs are expressed in humans. The highest affinity, CD64, is 
expressed on monocytes, dendritic cells and macrophages (11), mast cells (21), and 
neutrophils following IFN- exposure (22, 23). The low affinity CD32a is expressed on 
mast cells, neutrophils, macrophages, eosinophils and platelets (24). CD32c is 
expressed by 7-15% of individuals on NK cells and B cells and results from a gene 
mutation (4). The high/moderate affinity CD16a is expressed predominantly on NK cells, 
a subset of monocytes, mast cells, basophils, macrophages and is inducible in CD4+ T-
cells (25, 26). The low/moderate affinity CD16b is found only in humans and expressed 
predominantly on neutrophils (27), a subset of basophils (28) and has inducible 
expression on eosinophils (29, 30). CD32b is the sole inhibitory receptor and is 
expressed on basophils, B cells, macrophages, dendritic cells, a subset of monocytes 
and neutrophils (24). Interestingly, CD32b is also expressed in non-hematopoeitic cells, 
including the endothelium of various organs (31).  
 
Variability in receptor amount (JTR) 
Gene duplications in individuals lead to copy number variation (CNV) of some 
FcRs in the population. Surprisingly, only CD16a, CD16b and CD32c of the FcRs 
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exhibited CNV in a sample population of 600 subjects (32). CNVs have been correlated 
to autoimmune disorders as well as variations in surface expression levels. CNV of 
CD16b is correlated to surface expression on neutrophils and implicated in SLE 
susceptibility (33, 34), as well as other autoimmune disorders (35, 36). Furthermore, 
CD16a CNV appears to be functionally significant since increased surface expression 
positively correlated with increasing CD16a gene number (ranging from one to three 
copies) (32, 35). A CD16a indel has been shown to increase surface expression as well 
(37). 
FcR amount at the cell surface varies by cell type and receptor identity. On 
neutrophils, there are an estimated 100,000-300,000 surface exposed CD16b 
molecules and 10,000-40,000 CD32a molecules (38, 39). The predominant monocyte 
subtype at roughly 80% of the pool, “classical” monocytes, does not express CD16a. 
“Non-classical” monocytes express CD16a at a level of roughly 10,000 CD16a 
molecules per cell but upon differentiation into macrophages express 40,000 CD16a 
molecules per cell while CD32 remained the same at approximately 10,000 molecules 
per cell (40). Another study found macrophages express 5-10 fold higher CD64, CD32a 
and CD32b while CD16a expression was comparable to nonclassical monocytes. M2c 
macrophages expressed overall higher levels of FcRs than M1 macrophages with the 
following order of expression: CD32a, CD32b > CD64 > CD16a (41). A high number of 
CD16a molecules are expressed on CD16+ NK cells (100,000-250,000) (42). 
Expression levels also vary based on the cell status. Following activation, innate 
immune cells can induce expression of FcRs (23, 25, 29, 30, 35). There is also 
evidence of receptor downregulation upon activation. Downregulation mechanisms 
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include both decreases in expression as well as shedding FcR from the cell surface 
following metalloproteinase cleavage. CD32a is shed from Langerhans cells and also 
expressed as a soluble form (43). CD32b is shed upon activation of B-cells (44). CD16a 
and CD16b are likewise shed upon activation of NK cells and neutrophils at a known 
cleavage site by the metalloprotease ADAM17 (45-48). Intriguingly, sCD16b is relatively 
abundant in serum (~5 nM) (49) and levels vary based on the immune state of the 
individual (50). Surprisingly, CD64 is the only human FcγR in which a soluble, serum-
borne form has not been reported. This may be explained by the presence of a third 
extracellular CD64 domain in place of the cleavage site found in CD32s and CD16s. 
Soluble FcR forms modulate immune responses. Soluble CD16b binds myeloid 
cells, NK cells, subsets of T cells, B cells and monocytes through complement receptor 
3 (CR3 or Mac-1 or M 2, comprised of CD11b/CD18) and complement receptor 4 
(CR4 or x 2, co mprised of CD11c/CD18). These interactions cause the release of 
IL6 and IL8 by monocytes and indicate a potential role for soluble CD16b in 
inflammation (51). Shedding of CD16a from NK cells allows disengagement of the 
immune synapse from the target cell and the subsequent ability to kill again. One study 
demonstrated that repeated engagement by CD16a depleted perforin, however, 
shedding of CD16a allowed perforin replenishment upon subsequent activation by 
another activating receptor, NK group member D (NKG2D), which recognizes ligands 
not normally expressed on healthy tissue (52). Thus, it appears that the act of shedding 
of CD16 can allow disengagement of the foreign particle which would be crucial for the 
immune cell’s survival and preservation of potential future cytolytic activity. Though 
shed receptors are proinflammatory and recruit immune cells as discussed above, a 
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complete picture of the mechanisms of regulating surface expression upon immune 
activation is not currently available. 
 
Receptor clustering at the membrane is required for effector function (JTR) 
The correct presentation of FcRs on the cell membrane is essential for proper 
immune cell function. ADCC can destroy virally infected cells and cancer cells, and is thus 
a target for monoclonal antibody (mAb) therapies (53). ADCP is also an important 
mechanism in mAb therapy targeting malignant cells (14). ADCC and ADCP are 
dependent on the ability of low to moderate affinity FcRs to cluster on fluid plasma 
membranes for activation to occur (54) (Figure 1.1). Equally important is the regulation 
of these receptors when no activation signal is present. 
Proper activation of FcRs following Fc engagement by macrophages requires 
clustering of FcRs and the displacement of inhibitory receptors. In one study utilizing 
murine RAW 264.7 cells, segregation of CD45, a phosphatase responsible for 
dephosphorylating ITAMs, is dependent on antigen distance from the target membrane 
(55) (Figure 1.1). It appears that if the antibody is >10 nm from the target surface, there 
is a substantially impaired ADCP response. This phenomenon is due to the location of 
the epitope; epitopes closer to the surface exclude the inhibitory CD45 molecule (which 
stands ~22 nm tall vs. FcR-IgG complex = 11.5 nm) from the immune synapse. 
Interestingly, a follow-up study that focused on FDA-approved mAbs found the targets 
were small surface proteins (less than 10 nm in height) suggesting there may be a 
requirement for mAb epitopes to be located close to the surface for therapeutic efficacy. 
CD45 was also excluded from the immune synapse in activated human T cells (56). 
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Another study concerning inhibitory module segregation on human macrophages 
demonstrates CD64, but not CD32a, and inhibitory signal regulating protein  (SIRP), 
in conjunction with CD47 (a receptor that inhibits macrophage phagocytosis), are 
clustered on quiescent cells but upon activation segregate in a process regulated by 
spleen tyrosine kinase (SYK)-dependent actin cytoskeleton reorganization (57). 
Recently, FcR diffusion has been shown to be inhibited by the CD44 transmembrane 
protein which is immobilized by linearized actin filaments via ezrin/radixen/moesin 
(ERM) and binds hyaluronan in the glycocalyx (58). This study used primary human 
macrophages as well as murine cell lines and murine models, utilizing single particle 
tracking and found CD44 and hyaluronan decreased the diffusion rate of FcRs, while 
also sterically blocking the binding of FcRs to immune complexes (Figure 1.1).  
Receptor clustering overwhelms constitutive inhibition as described previously, 
allowing phosphorylation of the ITAM. ITAMs are phosphorylated via SYK, Src family 
kinase (SFKs) or -chain-associated protein kinase 70 (ZAP-70) for downstream 
activation of phosphoinositide-3-kinase (PI3K), NF-B, extracellular signal regulated 
kinase (ERK), phosphatidyl inositol 4-phosphate 5-kinase  (PIP5K) , GTPases and 
other SRC-family kinases (53,54, 59, 60). Along with FcR clustering, actin 
polymerization and depolymerization is equally important for phagocytosis in RAW 
264.7  macrophages by creating lammellipodium/pseudopods. These protrusions are 
controlled by Rac GTPase and lipid composition (54, 59) (Figure 1.1). Clustering has 
also been observed on the plasma membrane of murine derived macrophages using 
total internal reflection microscopy (TIRF) of a lipid bilayer supporting IgG (61). The 
FcR microcluster appears on the macrophage pseudopod edge and is subsequently 
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transported to a synapse-like structure thereby recruiting SYK and production of 
PtdIns(3,4,5)P3 coordinated with lamellar actin polymerization. Another study on 
quiescent human macrophages found lateral diffusion of FcRs is regulated by tonic 
activity of SYK causing actin cytoskeleton organization to increase the likelihood of 
FcRs to be pre-clustered upon finding a pathogen (62).This study further described 
differential FcR mobility upon activation. FcRs at the periphery of the actin-rich 
pseudopod were more mobile than those already immobilized by binding of IgG-rich 
regions. The authors explained that this mobility difference is controlled by SYK-
mediated regulation of the actin-cytoskeleton which would increase the likelihood of 
FcRs to engage more IgG molecules at the leading edge of the 
lamellipodium/pseudopod and not waste time diffusing into already IgG-dependent, 
FcR-immobilized, actin-rich rich regions of plasma membrane. Mobility of FcRs was 
described earlier to be decreased at the trailing end of polarized macrophages by CD44 
that was bound to linear actin and connected to hyaluronan (58). It was also found in 
this study that on the leading edge of polarized macrophages, the side that encounters 
opsonized material, Arp2/3-driven actin branching predominates, initiated by 
phosphotidlyinosotide (3,4,5)-trisphosphate production, and increased FcR mobility 
allowing for more efficient clustering at the immune synapse. When Arp2/3-driven actin 
branching predominates, it was found CD44 is more mobile allowing greater FcR 
mobility (Figure 1.1). 
 In the human NK92 cell line, transduced to express CD16, a study showed 2 
integrins mediate the dynamics of FcR receptor microclusters in a protein-tyrosine 
kinase 2 (Pyk2)-dependent manner, controlling the rate of target cell destruction by 
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ADCC (63). 2 integrins bind ICAM-1 on the target cell allowing adhesion and signal 
transduction through Pyk2 for actin remodeling and the subsequent enhancement of 
FcR mobility. Furthermore, sites of granule release are surrounded by clusters of CD16 
and release points are devoid of actin. Human NK cell lytic granules also converge at 
the surface in a dynein and integrin-signal dependent manner which aids spatial 
targeting of the weaponized molecules to limit off-target damage (64). Surprisingly, 
CD16a is essential for ADCC of human CD16+ monocytes and upon CD16a 
engagement, 2 integrins are activated along with TNF secretion thereby indicating 
that non-classical monocytes (CD16+) are the sole monocyte class capable of ADCC 
(65). 
During the early stages of phagocytosis by RAW 264.7 cells, direct contact 
between FcRs and IgG is increased by greater IgG density on particles, and increased 
IgG density results in an increased level of early signals. However, late stage signals 
are “all or nothing,” not concentration dependent, and regulated by PI3K concentration 
in the phagocytic membranes (66). In this study, low IgG density decreased the amount 
of opsonized particles but not the rate of phagosome formation and low IgG density 
particles that did result in phagocytosis recruited the same amounts of late stage 
signaling molecules (PIP3, Protein kinase C ε type, p85 subunit) and actin. Overall it 
appears that FcRs control the initial binding process essential for scanning the foreign 
particle and initial activation by binding IgG and later stages of commitment to 




On murine and human macrophages, receptor clustering upon activation is 
consistent with a change in the heterogeneity of the membrane lipid composition to a 
highly ordered phagosomal membrane that is heavily enriched in sphingolipids and 
ceramide but lacking cholesterol (67) (Figure 1.1). The authors state that lipid 
remodeling mediates F-actin remodeling and the biophysical characteristics of the 
phagosomal membrane are essential for phagocytosis. On human B cells, a 
polymorphism of the inhibitory receptor CD32b (Ile232Thr) located in the middle of the 
transmembrane domain, is described to decrease inhibitory function (68). This mutation 
was shown to result in aberrant localization to a sphingolipid and cholesterol rich region 
in contrast to the Ile232 wild-type. Aberrant localization is not surprising considering the 
introduction of a polar residue into the transmembrane domain (69). Furthermore, the 
ability of CD32b to inhibit B cell receptor (BCR)-mediated PIP3 production, AKT, 
phospholipase C--2 (PLC2) activation and calcium mobilization was impaired in cells 
expressing the CD16b Thr232 allotype as compared to Ile232. The authors indicate the 
FcR locus was associated with SLE and this polymorphism may promote disease. 
Thus, it appears lipid composition is important for FcR-mediated mechanisms. 
The unique construction of CD16b indicates the potential for a different activation 
mechanism for neutrophils. Neutrophils predominantly express CD16b with 10-fold less 
CD32a. CD32a signal transduction is well described and thought to be the canonical 
FcR signal transduction via phosphorylation of ITAMs and subsequent SYK recruitment 
(70). However, CD16b contains a GPI anchor and does not have a polypeptide 
transmembrane domain nor is it known to associate with a signaling coreceptor, 
therefore, it is unclear how CD16b promotes signaling in neutrophils. CD16b plays a 
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role in the initial binding of immune complexes in concert with 2 integrins (71). 
Currently there are conflicting studies suggesting that CD16b can transduce a signal on 
its own (70, 73, 73), or it transduces a signal by acting with CD32a (74). A recent study 
found that CD16b cross-linking increased IL-10 and TNF expression, phosphorylated 
SHP-2 in a lipid-raft mediated manner and inhibited apoptosis in neutrophils. Lipid 
composition certainly may be an important part of CD16b signal transduction in 
mechanisms similar to those discussed previously for macrophage phagocytosis and 
CD32b on B-cells, however the role of lipids in neutrophil activation is not understood 
(75-81). Interestingly proteinase 3 (PR3), CD16b, cytochrome b558, and NADPH 
oxidase co-immunoprecipitate on lipid rafts and PR3 and CD16b colocalize in confocal 
imaging suggesting these may interact in a lipid raft (75). Other findings suggest CD16b 
signals in conjunction with CR3 via lectin-like interactions (82), leading to neutrophil 
respiratory bursts (72). The function of GPI-linked CD16b remains undefined despite the 
high abundance of CD16b in the body and critical roles in mAb therapies (83). 
 
The type of FcR membrane anchor impacts activation (JTR) 
There are clear differences between the signaling and antibody-binding affinity of 
soluble and membrane-anchored FcR forms. However, less is known about the effects 
of the specific FcR membrane anchors on affinity and cell activation. All FcRs are 
localized to the membrane by a transmembrane polypeptide moiety or a 
glycosylphosphatidylinositol (GPI) moiety (CD16b only). A micropipette adhesion assay 
demonstrated that CD16a attached to microspheres via a GPI anchor bound roughly 5-
fold tighter to IgG1-coated red blood cells (RBCs) than CD16a tethered by a 
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transmembrane domain (84, 85). Interestingly, it also appears that IgG1-coated spheres 
treated with phosphoinositide phospholipase C (PIPLC) to remove the diacylglycerol 
moiety bound to GPI-linked CD16a with 12-fold less affinity. These authors observed a 
60-fold decrease when the GPI-anchor was completely removed. A CD16b-GPI 
construct showed 2-fold decrease of affinity upon PIPLC treatment and an 11-fold 
decrease following removal of the GPI-anchor. The authors hypothesized that 
enhancement of binding affinity associated with the GPI anchor may be due to an 
allosteric effect on CD16, changing the structure to bind IgG more effectively; such an 
allosteric mechanism was observed with other GPI-anchored proteins (80). Further 
studies will be required to fully elucidate how the GPI-anchor affects CD16b and how 
specific aspects of the membrane anchor confers distinct properties in vivo. 
 
N-linked glycosylation heterogeneity depends on multiple factors (JTR) 
Nearly half of all human proteins are estimated to be N-glycosylated making it 
one of the most abundant post-translational modifications (PTMs) (86). When a 
polypeptide contains the sequon N-X-S/T (X not being proline), a 14-residue sugar 
attached to the membrane through a dolichol phosphate  is transferred by 
oligosaccharryl transferase (OST) en bloc to the nascent polypeptide asparagine co-
tranlsationally (Figure 1.2) (87). N-glycosylation on the newly synthesized protein then 
serves functions in protein-folding and quality control pathways. Additionally, N-glycans 
protect the protein from proteolysis, reduce antigenicity, extend half-life in serum, 
promote secretion, contribute epitopes for receptor binding and affect protein structure 
(88-89). Glycosidases trim the N-glycans on properly folded glycoproteins upon 
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transportation through the ER and golgi network while glycosyl transferases transfer 
specific monosaccharides to the N-glycan. This processing can result in vast differences 
in N-glycan structure which lead to a heterogenous population of N-glycans in vivo. 
There are three main types of N-glycans; oligomannose, hybrid and complex-type 
(Figure 1.2). Oligomannose-type N-glycans are ‘minimally’ processed which escape 
remodeling by glycosyl transferases while being trafficked through the golgi network to 
the membrane surface or extracellular space. Complex-type N-glycans are highly 
processed by glycosyl transferases leading to complex, highly branched N-glycans. 
Hybrid-type N-glycans experience intermediate processing; the 6 branch contains only 
mannose residues while the 3 branch can be highly decorated like the complex-type 
N-glycan. N-glycosylation variation depends on enzyme abundance and localization 
along with substrate availability and abundance (90-91). Thus, N-glycosylation 





Figure 1.2. (JTR) N-glycosylation processing occurs in the ER and Golgi Network. A 14-sugar residue 
attached to the ER membrane through a dolichol phosphate is transferred by oligosaccharyl transferase 
co-translationally to a peptide containing the sequon, “N-X-S/T,” in which X is any amino acid residue 
except for proline. Glycosidases trim down the N-glycan as it is passed through the ER and cis Golgi 
Network. Gnt1 transfers an N-acetyl glucosamine to the 3 arm of the Man5 N-glycan allowing 
processing by downstream glycosyl transferases in the medial and trans Golgi. Enzymes in the medial 
and cis Golgi can modify the N-glycan with various monosaccharides as well as add branches allowing a 
diverse repertoire of N-glycan structure possibilities. Glycoproteins are then secreted or moved to the 
plasma membrane through vesicle transport systems. The three main N-glycan types include 
oligomannose, complex and hybrid-types. Minimally processed, oligomannose-type N-glycans can 
sometimes escape processing and be released to the extracellular space or transported to the plasma 
membrane. Complex-type are highly processed N-glycans which can be highly modified and/or branched 
with N-acetyl neuraminic acid ‘caps’. Hybrid types contain only mannose monosaccharides on the  arm 




N-linked glycosylation of antibody affects FcRIII (CD16) binding (JTR) 
IgG1 antibody affinities to FcRs are tuned by N-glycan composition as well as 
FcR polymorphisms. The CD16a V158 allele increases affinity 3-5 fold as compared to 
the CD16 F158 allele (92). mAb therapies have been described to have increased 
clinical efficacy in homozygous individuals with the higher affinity CD16a V158 allele as 
compared to homozygotes with the lower affinity CD16a F158 allele, directly correlating 
affinity to enhanced clinical outcomes (93-94). The N-glycan composition on IgG1 has 
been well described to modulate affinity to FcRIIIa (CD16a) and FcRIIIb (CD16b) (95-
102). The removal of fucose enhances affinity while addition of galactose increases 
affinity. Furthermore, a second generation of glycoengineered mAbs designed to take 
advantage of this effect have been described to enhance treatment outcomes, most 
likely due to these affinity enhancements (95-99). In addition to glycoengineered mAb 
therapies, serum IgG N-glycosylation has also become of interest because N-glycan 
composition changes with disease state as well as gender, infection, pregnancy and 
age which has been recently extensively reviewed by Gudelj et. al., 2018. (103-107). 
Previous studies have mainly focused on IgG glycosylation as compared to CD16a N-
glycosylation most likely because of the shear abundance of IgG in serum but have not 
looked at CD16a N-glycosylation. 
 
CD16a N-glycosylation composition affects binding to IgG1 (JTR) 
CD16a is N-glycosylated at 5 sites; N38, N45, N74, N162 and N169, and is 
expressed predominantly on NK cells and nonclassical monocytes as described in 
previous sections. CD16a N-glycosylation is important in its interaction with IgG. Edberg 
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and Kimberly found CD16a from NK cells expressed high amounts of oligomannose-
type N-glycans using lectin studies (108). Recent higher resolution mass spectrometry 
analysis of recombinant sources of CD16a N-glycosyation have been described to be 
much different to these lectin binding studies, granted these systems are expected to 
glycosylate proteins differently (101-102, 109-110). Edberg and Kimberly also found 
CD16 from NK cells bound IgG tighter than CD16 from monocytes and neutrophils 
suggesting differences in post-translational modifications to be the cause of this 
discrepancy (108). As described in previous sections, neutrophils express CD16b, a 
lower affinity FcR as compared to CD16a thus it was to be expected CD16 from 
neutrophils would bind IgG weaker (111-112). The reason for the vast differences in 
affinity between the two very similar proteins, CD16a and CD16b is detailed in Chapter 
3. sCD16b N-glycosylation from serum has recently been described by two groups and 
indeed express different glycoforms as compared to recombinant sources (113-114). 
Interestingly, these studies of CD16b from serum found N45 to express predominantly 
oligomannose-type N-glycans suggesting restricted processing at this site. 
CD16a N-glycan composition tunes affinity to IgG1. As described in a previous 
section IgG glycosylation is known to be able to affect protein interactions. Hayes et. al, 
2017 described differential binding kinetics of CD16a glycoforms expressed in NSO, 
CHO and HEK293f cells (102). Our group recently characterized the role of 
oligomannose-type N-glycosylation on CD16a as compared to complex-type (115). This 
study found CD16a is the only FcR which gets a significant enhancement in binding 
affinity (10-50-fold) when displaying an oligomannose-type N-glycan as compared to a 
complex-type, and this effect is specific to the N162 N-glycan. Previous studies by 
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independent groups have implicated the IgG fucose to prevent stabilizing carbohydrate-
carbohydrate interactions between the N162 N-glycan and the IgG1 N297 N-glycan 
(116-117). However, Falconer et. al. in our group thoroughly characterized the role of 
the N162 N-glycan using ITC, SPR and MD and found the N162 glycan clashes with the 
IgG1 N-glycan showing there was no stabilizing role of the N162 N-glycan (118). Thus, 
N-glycan composition on CD16a an N162 could tune affinity to antibody in vivo. 
 The discovery that CD16a N-glycan composition affects binding to IgG prompted 
our lab to develop methods to characterize N-glycosylation of CD16a from primary 
tissue. This has most likely not been performed before because material is extremely 
limited and technological advances in mass spectrometry in recent years have reached 
the sensitivity levels needed for the analysis. We estimate 1.5 liters of fresh blood would 
be needed to isolate enough cells to thoroughly characterize CD16a from NK cells and 
perhaps more from monocytes. In Chapter 2 we also elucidate the reason for the stark 
affinity difference between the very similar FcR’s; CD16a and CD16b. 
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CHAPTER 2. A SINGLE AMINO ACID DISTORTS THE FC  RECEPTOR IIIB / CD16B 
STRUCTURE UPON BINDING IMMUNOGLOBULIN G1 AND REDUCES AFFINITY 
RELATIVE TO CD16A 
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Roberts, J. T. & Barb, A. W. A single amino acid distorts the Fc γ receptor IIIb / CD16b 
structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a. J. Biol. 




Therapeutic mAbs engage Fc  receptor III (CD16) to elicit a protective cell-
mediated response and destroy the target tissue. Newer drugs designed to bind CD16a 
with increased affinity surprisingly also elicit protective CD16b-mediated responses. 
However, it is unclear why immunoglobulin G (IgG) binds CD16a with more than 10-fold 
higher affinity than CD16b even though these receptors share > 97% identity. Here, we 
identified one residue, Gly129, that contributes to the greater IgG-binding affinity of 
CD16a. The CD16b variant D129G bound IgG1 Fc with two-fold higher affinity than 
CD16a and with 90-fold higher affinity than WT. Conversely, the binding affinity of 
CD16a-G129D was decreased 128-fold relative to WT CD16a and comparably to that of 
WT CD16b. The interaction of IgG1 Fc with CD16a, but not with CD16b, is known to be 
sensitive to the composition of the asparagine-linked carbohydrates (N-glycans) 
attached to the receptor. CD16a and CD16b-D129G displaying minimally processed 
oligomannose N-glycans bound to IgG1 Fc with about 5.2-fold increased affinity 
compared with variants with highly processed complex-type N-glycans. CD16b and the 
CD16a-G129D variant exhibited a smaller 1.9-fold affinity increase with oligomannose 
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N-glycans. A model of glycosylated CD16b bound to IgG1 Fc determined to 2.2 Å 
resolution combined with a 250-ns all-atom molecular dynamics simulation showed that 
the larger Asp129 residue deformed the Fc-binding surface. These results reveal how 
Asp-129 in CD16b affects its binding affinity for IgG1 Fc and suggest that antibodies 




Immunoglobulin G (IgG) opsonizes a previously encountered pathogen to target 
it for destruction by eliciting an immune response. IgG binds the target with high 
specificity through the antigen binding fragments (Fabs) and interacts with innate 
immune system effector cells through the crystallizable fragment (Fc) by engaging Fc  
receptors (FcRs), thus bridging the adaptive and innate immune systems (Figure 2.1). 
There are three classes of cognate human FcRs: FcRI (CD64), FcRII (CD32) and 
FcRIII (CD16) (1). CD16 is of particular interest because it is the primary receptor 
responsible for antibody-dependent cell mediated cytotoxicity (ADCC) and thus tumor 
clearance (2,3). Two CD16 forms, CD16a and CD16b, bind to IgG1 with surprisingly 
different affinities considering the high degree of structural and sequence similarity 
(4,5). In this manuscript we probe the contribution of an amino acid residue to the 
different binding affinities of CD16a and CD16b. 
CD16a is an integral membrane protein predominantly expressed on NK cells 
and monocytes. CD16b is predominantly expressed with a glycosylphosphatidylinositol 
anchor on neutrophils, a subset of basophils and shows inducible expression on 
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eosinophils (6-12) (Figure 2.1). CD16a has two predominant alleles (V158 or F158) and 
CD16b has two predominant alleles including human neutrophil antigen 1 (HNA-1 or 
NA1) and NA2 (13,14). CD16a-V158 and CD16b-NA2 share >97% sequence identity 
and differ by only four amino acid residues in the extracellular antibody-binding domains 
(Figure 2.1B). Despite the significant homology shared by CD16a and CD16b, CD16a 
binds antibody more than 10-fold tighter though it is unclear how differences in these 
four amino acids contribute to differences in binding affinity (5). Only one of these four 
differences, at position 129, forms part of the IgG1-binding interface. 
FcRs are heavily modified with asparagine-linked carbohydrates (N-glycans; for 
a review of N-glycosylation see (15)). CD16a has as many as five N-glycans and 
CD16b (NA2) has as many as six though it is not clear if all sites are fully occupied. N-
glycan composition of CD16 appears to be varied, depending upon the type of 
expressing cell and it was shown that different cells bind IgG with different affinity 
through CD16 (16-19). Three recent studies reported that the binding affinity of CD16a 
is influenced by receptor N-glycan composition (19-21). In one example, CD16a with 
minimally-processed Man5 N-glycans bound 12-fold tighter to IgG1 Fc (G0F) than 
CD16a with highly-processed and elaborated complex-type N-glycans but glycan 
composition only impacted CD16b affinity by less than 2-fold (examples of different N-
glycoforms are shown in Figure 2.2) (19,22). This result is surprising considering the 
significant homology shared by CD16a and CD16b (Figure 2.1). The CD16a N-glycan 
at position 162 mediated this effect that likewise may be influenced by the nearby Gly-




Figure 2.1. Fc  receptor (FcR) III/CD16 is expressed in two forms from two distinct genes. A) 
FcRIIIb/CD16b is highly expressed on neutrophils and FcRIIIa/CD16a is the predominant FcR 
expressed on natural killer (NK) cells. B) These proteins differ by only four amino acid residues 
(highlighted in yellow) in the mature proteins. The N-terminal signal peptide is indicated in red and is not 
found in the fully processed proteins. The C-terminal residues of CD16b shown in orange are cleaved 
prior to addition of the GPI anchor at the newly uncovered C-terminal serine. N-glycosylation sites are 
indicated with grey shading. Both proteins are cleaved by ADAM17 and released from the cell surface 




N-glycan composition of the IgG1 crystallizable fragment (Fc) is a well-known 
variable in CD16 binding affinity (3,23-26). This property directly impacts the 
development of therapeutic monoclonal antibodies (mAbs) because increasing affinity 
for CD16 increased therapeutic efficacy (13,25,27-29). A major advance for mAb 
development occurred with the observation that IgG lacking a prevalent antibody 
modification, L-fucose attached to the core (1)GlcNAc residue of the N-glycan, 
increased binding affinity and ADCC (30). This observation inspired the development of 
many new glycoengineered mAb therapies (31-34). Notably, CD16b demonstrated a 
larger enhancement in binding non-fucosylated IgG1 Fc in vitro when compared to 
CD16a in vitro (5). The current generation of glycoengineered antibodies are more 
effective at binding to CD16b on neutrophils and eliciting effector responses, showing 
greater therapeutic potential (35,36). These studies support the development of mAbs 
that bind CD16b with higher affinity to mobilize an effective neutrophil response. 
However, the development of future mAbs is limited by a lack of information regarding 
the detailed mechanism and identification of which residues contribute to the reduced 
affinity of CD16b for IgG1 Fc when compared to CD16a. 
A comparison of the amino acid sequences for CD16b and CD16a reveals only 
one of the four differences in the antibody-binding domains, at position 129, directly 
contributes the interface formed with IgG1 Fc (Figure 2.1B). If Asp-129 of CD16b 
disrupts this interface, then CD16b D129G is expected to bind as tightly as CD16a and 
CD16a G129D will bind with less affinity. Furthermore, if CD16a Gly-129 contributes to 
the sensitivity of affinity to receptor N-glycan composition, then CD16a G129D should 
no longer be sensitive to N-glycan composition. In this manuscript, we evaluate how 
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Gly-129 and Asp-129 impact the affinity of CD16 for IgG1 Fc. We also determined how 
these residues modulate the differential sensitivity of CD16a and CD16b to N-glycan 
composition.    
 
Figure 2.2. Total ion current of procainamide-derivatized CD16b N-glycans expressed in two distinct 
glycoforms and analyzed by HILIC-MS. (top) CD16b was expressed to display oligomannose (Man5) N-
glycans. (bottom) CD16b with complex-type (CT) N-glycans. 
 
Results 
N-glycomics of the recombinant proteins 
In order to evaluate the impact of N-glycan composition and Asp-129 v. Gly-129 
on CD16 structure and IgG1 Fc binding, we expressed four CD16 variants including 
CD16a, CD16a G129D, CD16b and CD16b D129G, using two cells lines that resulted in 
a panel of eight receptor variants. One cell line, HEK293F, contains a large repertoire of 
glycan modifying enzymes and expressed CD16 with a heterogeneous mixture of highly 
branched complex-type N-glycans (Figure 2.2). The second cell line, HEK293S, 
contains a defect in the GNT1 gene (37,38) and expressed CD16 with predominantly 
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Man5 oligomannose-type N-glycans though small amounts of Man6, Man7, Man8 and 
Man9 were also present (Figure 2.2). 
 
rCD16b D129G-CT binds IgG1 Fc with affinity comparable to rCD16a-CT 
Wild type recombinant (r)CD16a-CT bound IgG1 Fc glycoforms with affinities 
between 38- and 60-fold tighter than rCD16b (Figure 2.3 and Table 2.1). These values 
were comparable to previous results from our laboratory, however, the binding of 
rCD16a-CT is roughly 1.5 to 4-fold tighter (5,20). As predicted, rCD16a-CT bound IgG1 
Fc with more than 100-fold greater affinity than rCD16a G129D-CT. The rCD16a 
G129D-CT variant bound with an affinity comparable to rCD16b-CT (22 mM v 6.4 mM, 
respectively; Figure 2.4). In the complementary experiment, rCD16b-D129G-CT bound 
at least 64-fold tighter to three IgG1 Fc N-glycoforms than rCD16b-CT. Furthermore, the 
affinities of rCD16a-CT and rCD16b D129G-CT were less than 3.1-fold different, 
confirming the importance of a Gly at position 129 in high-affinity IgG1 Fc binding. It is 
possible that subtle differences in N-glycan composition resulting from expression 
conditions, in particular the N-glycan at Asn-162, impact the measured affinity. This 
effect is noted for CD16b D129G-CT that contains a larger amount of oligomannose N-





Figure 2.4. A glycine at position 129 of CD16 is essential for high affinity IgG1 Fc binding. Dissociation 
constants indicate the impact of the IgG1 Fc N-glycan, CD16 in N-glycan and residue at position 129 on 
binding affinity. Error bars indicate the error-of-fit for the interactions. 
 
Table 2.1. Binding affinity measurements with two receptor glycoforms and three IgG1 Fc glycoforms 
determined by surface plasmon resonance. 
 IgG1 Fc G0F  IgG1 Fc G2F  IgG1 Fc G0 
Receptor KD (nM) ± err  KD (nM) ± err  KD (nM) ± err 
rCD16a-CT 140 10  70 2  25 1 
rCD16a G129D-CT 22000 1000  12500 600  3000 200 
rCD16b-CT 6400 400  4200 300  950 100 
rCD16b D129G-CT 100 10  48 3  8 1 
rCD16a-Man5 48 2  22 1  3.9* 1.0 
rCD16a G129D-Man5 9500 300  4000 200  1100 100 
rCD16b-Man5 5200 300  2900 200  560 30 
rCD16b D129G-Man5 13 1  6.0 0.3  3.6* 1.0 




















Tighter-binding CD16 variants are sensitive to N-glycan composition 
Comparing the binding affinities of the CD16 variants with different N-glycan 
composition provided insight into the role of Gly-129 in the higher affinity interactions. 
All receptor variants bound tighter with oligomannose N-glycans, however, receptors 
with a Gly residue at position 129 showed an average affinity increase of 5.2 ±2.6-fold 
compared to 1.9 ±0.8-fold for receptors with an Asp residue at position 129 (Table 2.1). 
 
The CD16 129 residue impacts association and dissociation of IgG1 Fc 
The receptor variants that bound with lower affinity revealed very fast apparent 
association and dissociation kinetics using the relatively high concentrations of analytes 
required to reach saturation (CD16b and CD16a G129D). These rates were too rapid to 
accurately estimate from the SPR sensorgrams because binding was limited by the rate 
of analyte flow over the chip surface (Figure 2.3). Conversely, variants that bound with 
higher affinity showed slower observed association and dissociation rates (CD16a and 
CD16b D129G). These observed rates appeared slow due to the small amounts of 
receptor used for the binding measurements and are not comparable to the association 
rates measured for the low affinity variants that were tested at much higher analyte 
concentrations and likely bind with equal or slower on rates. As a result, the 
associations for the high affinity variants failed to reach equilibrium after 800 s and only 
an analysis of binding kinetics provided appropriate estimates of KD (Figure 2.3 and 
Table 2.2). Reactions that permitted KD measurement using both equilibrium and kinetic 
data revealed comparable results and validated the direct comparison of KDs measured 





Figure 2.3. The binding affinity and binding kinetics of the CD16b D129G protein are comparable to the 
high affinity CD16a protein. Shown are representative binding sensorgrams for the CD16 variants binding 
to IgG1 Fc (G0 glycoform). Dissociation constants are determined using equilibrium intensity values with 
the exception of those KDs marked with an asterisk (*) that were calculated by fitting kinetic data. Errors 
indicate uncertainties from the curve fitting procedures. 
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Table 2.2. Association and dissociation rate constants measured from kinetic fits of the surface plasmon 
resonance sensorgrams. 





± err kOFF 
(s-1) 




± err kOFF 
(s-1) 
± err KD 
(nM) 
rCD16a-CT 39 11% 0.00506 14% 130 98 13% 0.00420 10% 43 
rCD16b D129G-CT 306 18% 0.01853 16% 61 317 4% 0.00323 10% 100 
rCD16a-Man5 437 19% 0.01729 16% 40 625 1% 0.00242 29% 3.9 
rCD16b D129G-Man5 422 2% 0.00440 18% 10 685 4% 0.00246 20% 3.6 
 
Among the high-affinity variants, it is notable that rCD16a-CT bound to IgG1 Fc 
G0F and G0 with the slowest of the measured on-rates (39 and 98 mM-1 s-1, 
respectively, compared to 306–685 mM-1 s-1; Table 2.2). Surprisingly, rCD16b D129G 
bound with a 3 to 8-fold faster kON compared to rCD16a but more similar kOFFs (0.8 to 
3.7-fold difference). These differences contribute to KDs that were no more than 2.1 to 
2.3-fold different. This result indicates that substitution at residue 129 does not transfer 
the complete kinetic properties between CD16a and CD16b.  
 
The structure of glycosylated CD16b in complex with IgG1 Fc 
Three models of IgG1 Fc bound to non-glycosylated CD16b revealed the 
structural features of low-affinity FcRs bound to antibody (39,40). However, the 
availability of moderate resolution diffraction (3.0–3.5 Å), moderate Rfrees (0.28–0.36) 
and high temperature factors for the Asp-129 backbone atoms (78-104 Å2) limit the 
ability to formulate hypotheses regarding the position of individual atoms at the Fc-
receptor interface and compare to three higher quality structures of the CD16a:IgG1 Fc 
complex (2.2 Å with Rfrees = 0.24–0.26 (20,41,42)). One feature of the higher-quality 
CD16a complexes is the presence of the Asn-45 and Asn-162-glycans. Multiple reports 
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highlighted the importance of these two N-glycans and the dispensability of the 
remaining three N-glycans to IgG1 Fc binding affinity (20,43,44). To improve the crystal 
quality we prepared glycosylated rCD16b-Man5 with four of the six N-glycosylation sites 
removed by mutating the modified Asn residue to a Gln (N38Q/N64Q/N74Q/N169Q). 
Indeed, this rCD16b-Man5 variant bound IgG1 Fc with 0.7 to 0.9-fold of the affinity 
observed using rCD16b-Man5 and indicated a suitability for crystallization trials (Table 
2.1). 
 
Figure 2.5. CD16a binds IgG1 Fc with greater affinity and makes a closer approach to IgG1 Fc through 
the loop containing residue 129. The overall complexes formed by A) CD16a and B) CD16b with IgG1 Fc 
are highly similar with an rmsd = 0.499 Å. Protein backbone is shown as ribbons and N-glycans are 
shown as sticks. C) Electron density of the CD16b region surrounding Asp-129 is well resolved at 1.5 . 
D) The Gly-129 amide nitrogen atom of CD16a is located 1.3 Å closer to the carbonyl carbon of the IgG1 




 Two crystal forms of the rCD16b-Man5:IgG1 Fc complex diffracted to high 
resolution. One form crystallized in the P212121 space group and diffracted to 2.5 Å 
(data not shown). A second crystal in the C2 space group diffracted to 2.22 Å with high 
completeness (data not shown). The CD16a-IgG1 Fc complex provided initial phases 
(20) and the iterative refinement of the higher resolution data resulted in an Rfree = 
0.2477 as well as a model with no Ramachandran outliers and only 1.2% of sidechain 
rotamer outliers. As expected, the overall structure is highly similar to other CD16a and 
CD16b models (Figure 2.5). This structural model has an r.m.s.d. of 0.499 Å when 
compared to the rCD16a-Man5:IgG1 Fc complex  (pdb 5vu0; (20)) and 2.054 Å when 
compared to a non-glycosylated rCD16b:IgG1 Fc complex (pdb 1T89; (40)).  
 
The Asp-129 residue of CD16b distorts the Fc-binding interface 
In addition to higher resolution data and higher refinement scores when 
compared to previous CD16b:IgG1 Fc complexes, the model calculated from the 2.22 Å 
dataset provided low temperature factors for the interface residues with values for the 
Asp-129 backbone atoms ranging from 42 to 43 Å2 (compared to 78-104 Å2 for previous 
CD16b models). These lower values allow comparison to CD16a models with similar 
quality (Figure 2.5C). Despite the high degree of amino acid similarity, the interface 
formed between CD16b and IgG1 Fc is smaller and involves less residues than the 
interface formed by CD16a (data not shown). The buried surface area measured with 
this model is 860 Å2 and comparable to previous CD16b models (1t89= 737 Å2 and 
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1e4k = 816 Å2 (39,40)). These areas are less than those measured with the CD16a-
IgG1 Fc complex (3sgj = 1193 Å2, 3ay4 = 924 Å2, 5vu0 = 897 Å2 (20,41,45).  
 
Figure 2.6. Asp-129 in CD16b decreases the distance between beta strands and distorts the interface 
formed between the Asn-162-glycan and Arg-155 when compared to Gly-129 and CD16a. A) The CD16a 
complex with glycosylated CD16a is shown in red (pdb 5vu0 (20)) and superimposed on the unliganded 
(“unlig.”) CD16b (pdb 1e4j (39)) shown in gray. Note that the position of the Asp-129 sidechain clashes 
with the IgG1 Fc C'E loop. B) Glycosylated CD16b in complex with IgG1 Fc is shown in orange and 
superimposed on the unliganded (“unlig.”) CD16b shown in gray.  IgG1 Fc binding distorts the 
conformation surrounding Asp-129, shortening the distance from Asp-129 to Arg-155. C&E) Two views of 
CD16a with the polypeptide surface shown in grey and relevant residues as red sticks. D&F) Two poses 
of CD16b with the polypeptide surface shown in grey and relevant residues as orange sticks. This Asp-
129-mediated strand distortion perturbs the interface formed between the (1)GlcNAc residue of the CD16 
Asn-162-glycan and Arg-155.  
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Asp-129 represents the only amino acid difference between CD16b and CD16a 
that is found at the interface formed with IgG1 Fc. The close approach of the CD16a 
Gly-129 amide nitrogen to the IgG1 Fc Tyr-296 carbonyl (3.2 Å) is prevented by the 
CD16b Asp-129 residue, increasing this internuclear distance to 4.5 Å and distorting the 
CD16b backbone (Figure 2.5D-E). Surprisingly, it appears that this distortion is not 
present in the absence of IgG1 Fc; a model of unliganded CD16b reveals an identical 
backbone conformation to CD16a in the region of Asp-129 (Figure 2.6A). The observed 
conformation in the unliganded CD16b model places the Asp-129 sidechain within the 
van der Waals radii of the IgG1 Fc Asn-297 residue. Thus, CD16b must deform to 
accommodate IgG1 Fc, distorting the backbone. These changes at the Fc interface 
potentially explain why CD16b binds IgG1 Fc weaker than CD16a. 
The backbone distortion due to Asp-129 impacts the local tertiary structure, 
deforming the beta sheet and reducing the distance across the sheet by 1.2 Å when 
compared to CD16a (as measured by the distance to Arg-155; Figure 2.6A-B). This 
change impacts the conformation of the Arg-155 sidechain which forms an interface 
with the Asn-162-glycan (1)GlcNAc residue in the CD16a complex. In the CD16b 
complex, the contacts between Arg-155 and the (1)GlcNAc residue are reduced as the 
Arg-155 sidechain shifts away from the carbohydrate (Figure 2.6C-F). This impact on 
the intramolecular interface formed between the Asn-162 glycan (1)GlcNAc residue and 
the Arg-155 sidechain may explain why the affinity of IgG1 for CD16a, but not CD16b, is 





MD simulations of the CD16b-IgG1 Fc complex 
Measurements of binding affinity pinpointed the residue at position 129 as a 
critical difference between CD16a and CD16b. X-ray crystallography highlighted 
differences in the interfaces formed by these receptors and IgG1 Fc. However, these 
data represent a single conformational snapshot and it remained unclear whether X-ray 
crystallography only captured a representative state. The N-glycosylated CD16b-IgG1 
Fc complex served as a starting point for a 250 ns all-atom molecular dynamics 
simulation to compare to a recent 250 ns simulation of the CD16a-IgG1 Fc complex to 
assess the stability of the observed interactions on this timescale (20). Though this 
simulation timescale is insufficient to probe all potential conformations accessed by 
these proteins, it may prove informative of differences in local conformation, potentially 
governed by low energetic barriers that would be sampled in a relatively restricted 
simulation.  
 Distances separating the CD16 129 residue and the IgG1 Fc C'E loop showed 
values consistent with the models determined by X-ray crystallography: the CD16b Gly-
129 C atom was 4.6 Å from the Fc Asn-297 C compared to 3.9 Å for the CD16a 
complex (Figure 2.6). Though the average distances observed with MD are slightly 
larger (5.0 and 4.3 Å, respectively), the differences of 0.7 Å are identical (Figure 2.7). 
These greater distances for CD16b separated the CD16a Gly-129 N and Fc Tyr-296 O 
atoms (ave = 4.8 Å) which participated in a H-bond in the CD16a simulations (ave = 3.0 
Å). In the CD16b simulations and model determined by x-ray crystallography, this H-
bond was replaced by an interaction with the CD16b Lys-128 N atom which sampled 
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distances within H-bond range in the CD16b simulation but not in the CD16a simulation 
(Figure 2.7, bottom panels). 
 
 
Figure 2.7. Internuclear distances observed in crystallography are maintained during 250 ns all-atom 
molecular dynamics simulations of the CD16 – IgG1 Fc complexes. Panels in the left column indicate a 
10-frame average of each distance over the course of the simulation. The right panels show histograms 
reporting the number of frames that correspond to each distance. Vertical arrows indicate the distance 
measured from structures determined by X-ray crystallography (CD16a – IgG1 Fc G0 (pdb 5vu0 (20)); 
CD16b – IgG1 Fc G0 this manuscript). Distances correspond to those measured in Figures 2.5 and 2.6. 




 Simulation likewise preserved the observed deformation of the CD16b beta sheet 
induced by Asp-129 that reduced the distance between the Arg-155 and 129 C atoms 
by 1.2 Å compared to CD16a (Figure 2.6A and 2.B). Though the difference in averages 
is somewhat smaller in the simulations at 0.8 Å, the same trend is observed until the 
very end of the CD16b simulation (Figure 2.7). Interestingly, CD16b drifts slightly away 
from IgG1 Fc in the final 30 ns of the simulation as indicated by the increasing distances 
between CD16b Asp-129 and Fc residues Asn-297 and Tyr-296. At the same time, the 
beta sheet deformation also disappears and the distance between the CD16b Arg-155 
and Gly-129 C atoms matches the CD16a simulation (9.6 Å). This observation 
supports the conclusion that complex formation and contact with the IgG1 Fc C'E loop 
impinges upon the CD16b Asp-129 residue. 
 
Discussion 
 The data presented here demonstrate that a single amino acid residue at position 
129 accounts for the major differences in binding affinity, binding kinetics, and sensitivity 
to receptor N-glycan composition. The presence of a Gly at CD16 residue 129 supports 
high affinity IgG1 Fc binding but an Asp residue, as found in CD16b, reduces affinity. 
These data are supported by binding measurements and the structural model of the N-
glycosylated CD16b-IgG1 Fc complex determined by X-ray crystallography. Extensive 
all-atom MD simulations further supported differences in the CD16-IgG1 Fc models. 
 The deformation of CD16b due to Asp-129 upon complex formation with IgG1 Fc 
likely contributes an energetic penalty that prevents CD16b from binding as tightly as 
CD16a. This is evident upon examining a model of unliganded CD16b that showed 
47 
 
indistinguishable backbone geometry compared to CD16a in complex with IgG1 Fc 
(Figure 2.6). Furthermore, this deformation reduced the buried surface area formed in 
the complex. With these data alone it is not possible to quantify the impact of the 
deformation on IgG1 Fc binding affinity because it is not clear how Asp-129 impacts 
conformational sampling of unliganded CD16b. Robinson et al. recently noted evidence 
for sampled conformation differences between CD16a and CD16b and developed a 
CD16a-selective affimer, AfG3, that binds between the two extracellular domains to a 
region with conserved amino acids in CD16a and CD16b (46). Though the authors 
believe the selectivity of AfG3 is largely due to H-bonds formed by CD16a Arg-18 
(CD16b NA2 S18), it is clear that amino acid differences distant from the IgG1-binding 
surface of CD16 can impact conformational sampling.  
It is surprising that CD16a is more sensitive to N-glycan composition than 
CD16b, and that this behavior is influenced by the residue at position 129. As stated, 
CD16a N-glycan composition affects affinity for binding IgG1 Fc (16,19,21). The data 
presented here further support the recent observation that CD16a is the only FcR 
sensitive to receptor N-glycan composition (Table 2.1 and (22)). Furthermore, the 
analysis of the CD16 amino acid variants binding to IgG1 Fc highlights the central role 
of CD16a Gly-129 in this unexpected behavior. The structure of glycosylated CD16b in 
complex with IgG1 Fc provides some insight into the mechanism underlying this 
phenomenon: Asp-129 deforms the CD16b beta sheet adjacent to the interface formed 
with IgG1 Fc and this distortion perturbs contacts between the Asn-162-glycan and Arg-
155 (Figure 2.6). Though it is unclear why CD16a with Man5 N-glycans binds tighter to 
IgG1 Fc than CD16a with complex-type N-glycans, the ability to increase the sensitivity 
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of CD16b to N-glycan composition by the D129G substitution indicates residues 
surrounding Gly-129 are likely involved in this phenomenon. 
CD16b has received much less attention than CD16a. Though engaging CD16a 
is essential for the therapeutic activity of most mAbs, CD16b has emerged as an 
important target (35). The recent realization that targeting CD16b may improve these 
drugs is partially due to the roughly 50-fold higher amount of CD16b in the human body 
compared to CD16a. We estimate that the average person contains more than 200 g 
of CD16b from neutrophils in circulation compared to just 4 g of CD16a from 
monocytes and NK cells (2,19,47). Perhaps because of this difference in abundance, 
mAbs that specifically target CD16b provide definite advantages. One glycoengineered 
anti-CD20 antibody, obinutuzumab, showed greater therapeutic efficacy than the 
standard anti-CD20 therapy rituximab due to higher affinity and an ability to activate 
neutrophils through CD16b but not CD32a (35). Another study also found 
glycoengineered nonfucosylated rituximab similarly enhanced neutrophil activation 
through CD16b engagement (36). These findings demonstrate that increasing the 
CD16b binding affinity of mAbs provides better therapeutic responses and potentially 
lower doses in the clinic. Our finding that the Asp-129 substantially decreases rCD16b 
affinity for IgG1 Fc indicates that designing antibodies to accommodate the Asp-129 









All materials were purchased from Sigma-Aldrich unless otherwise noted. 
 
Protein expression and purification 
CD16a (V158) and CD16b (NA2) were previously cloned into the Not1 and 
EcoR1 restriction sites of the pGen2 vector (5,48,49). CD16a and CD16b cloned into a 
pUC57 vector served as templates to generate genes encoding mutated receptors 
according to the QuikChange protocol (Agilent). Mutations were verified by DNA 
sequencing at the ISU DNA Facility. Verified mutant genes were subcloned into the 
pGen2 plasmid using the Not1 and EcoR1 restriction enzymes (49).  
The expression and purification of CD16 with complex-type N-glycans was 
achieved by expressing from HEK293F cells and purified as previously described (5). 
CD16 with oligomannose (Man5) N-glycans was expressed using the HEK293S cell line 
as previously described (19). Typical yields were ~0.2 mg/mL of final culture volume. 
IgG1 Fc used for binding analyses and single IgG1 Fc glycoforms were prepared as 
previously described (5). Binding analyses for the previous 2016 report and the results 
reported in this current manuscript were collected within a few days of one another. 
IgG1 Fc lacking a fucose residue was used for crystallography and was prepared by 
expressing protein in the presence of 250 M 2-fluoro-2-deoxy fucose as previously 
described (5). Glycomics analyses of PNGaseF released N-glycans using HILIC-ESI-




Crystallization of CD16b-IgG1 Fc complex 
CD16b-N38Q/N64Q/N74Q/N169Q with Man5 N-glycans was transferred to a 
buffer containing 50 mM tris(hydroxymethyl)aminomethane, 100 mM sodium chloride 
and 0.5 mM ethylenediaminetetraacetic acid, pH 8.0. A 1:50 molar ratio (receptor:TEV-
GFP) was added and the samples incubated overnight in the dark at room temperature. 
CD16 was separated from GFP by flowing over a Ni-NTA resin (Qiagen) and 
concentrating the flow through fractions containing CD16. CD16 was exchanged into a 
buffer containing 20 mM 3-(N-morpholino)-propanesulfonic acid, 100 mM sodium 
chloride, pH 7.2 with an Amicon Ultra centrifugal filter with a 10 kDa molecular weight 
cutoff (Merck Millipore). CD16 was then mixed with IgG1 Fc (-fucose) at a (1:1.5) molar 
ratio. Complex was separated from unbound IgG1 Fc by purification with an AKTA pure 
chromatography system equipped with a Superdex 200 gel filtration column 
preequilibrated with a buffer containing 20 mM 3-(N-morpholino)propanesulfonic acid, 
100 mM sodium chloride, pH 7.2 (GE Healthcare Bio-Sciences). Fractions containing 
the CD16:Fc complex were identified by SDS-PAGE and concentrated to 12 mg/mL. 
Crystals in the P212121 space group were obtained using the hanging drop method 
with a well solution of 50 mM 2-(N-morpholino)ethanesulfonic acid, 10% PEG3350 (w/v) 
and 50 mM sodium chloride, pH 6.0. Crystals in the C2 space group were obtained 
using the hanging drop method with a well solution of 50 mM 2-(N-morpholino)-
ethanesulfonic acid, 8% PEG3350 (w/v) and 60 mM sodium chloride. All crystals were 
cryoprotected with 15% ethylene glycol diluted with well solution and flash frozen in 
liquid nitrogen. Diffraction data was collected at 1° increments for 200 frames with an 
exposure time of 0.5 seconds on beamline 23-ID-D at the Argonne National Laboratory 
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Advanced Photon Source (APS) with a Pilatus3 6M detector. The software HKL-3000 
was used to index, scale and merge datasets. Initial phases were determined with 
molecular replacements in Phenix-Phaser MR using the PDB id# 5vu0 (20). Final 
refinement was performed with Phenix using secondary structure restraints and 
noncrystallographic symmetry restraints. The structure was deposited in the PDB as 
6eaq. Measurements of interfaces and buried surface area were made using the 
PDBePISA utility (50). Molecular dynamics simulations of the glycosylated CD16b-Fc 
complex were performed using Amber16 as described (20). 
  
Surface Plasmon Resonance (SPR) binding experiments 
Binding experiments were performed as described (5). For interactions that 
reached a clear equilibrium, intensity values of the association phase were fitted with a 
binding isotherm to determine a dissociation constant for the interaction. For slower 
interaction where a clear equilibrium was not achieved, dissociation constants were 
calculated using the observed on and off rates as described (5). Values for Tables 2.1 
and 2.2 include errors resulting from the least-squares fitting procedure.  
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CHAPTER 3. SITE-SPECIFIC N-GLYCAN ANALYSIS OF ANTIBODY-BINDING FC  
RECEPTORS FROM PRIMARY HUMAN MONOCYTES 
 
A manuscript submitted to Molecular and Cellular Proteomics 
 
Abstract 
FcRIIIa (CD16a) and FcRIIa (CD32a) on monocytes are essential for proper 
effector functions including antibody dependent cellular cytotoxicity (ADCC) and 
phagocytosis (ADCP). Indeed, therapeutic monoclonal antibodies (mAbs) that bind 
FcRs with greater affinity exhibit greater efficacy. Furthermore, post-translational 
modification impacts antibody binding affinity, most notably the composition of the 
asparagine(N)-linked glycan at N162 of CD16a. CD16a is widely recognized as the key 
receptor for the monocyte response, however the post-translational modifications of 
CD16a from endogenous monocytes are not described. Here we isolated monocytes 
from individual donors and characterized the composition of CD16a and CD32a N-
glycans from all modified sites. The composition of CD16a N-glycans varied by 
glycosylation site and donor. CD16a displayed primarily complex-type biantennary N-
glycans at N162, however some individuals expressed CD16a V158 with ~20% hybrid 
and oligomannose types which increased affinity for IgG1 Fc according to surface 
plasmon resonance binding analyses. The CD16a N45-glycans contain markedly less 
processing than other sites and >75% hybrid and oligomannose forms. N38 and N74 of 
CD16a both contain highly processed complex-type N-glycans with N-acetyllactosamine 
repeats and complex-type biantennary N-glycans dominate at N169. The composition of 
CD16a N-glycans isolated from monocytes included a higher proportion of 
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oligomannose-type N-glycans at N45 and less sialylation plus greater branch 
fucosylation than we observed in a recent analysis of NK cell CD16a. The additional 
analysis of CD32a from monocytes revealed different features than observed for CD16a 
including the presence of a predominantly biantennary complex-type N-glycans with two 
sialic acids at both sites (N64 and N145). 
 
Introduction 
Circulating leukocytes express Fc  receptors (FcRs) that trigger a protective 
response after encountering an antibody-coated target cell. Therapeutic monoclonal 
antibodies (mAbs) represent a rapidly growing class of drugs that are highly specific and 
generally well tolerated. The global market for mAbs, estimated at $90B in 2015, is 
expected to meet or exceed $140B by 2024 with many new drugs in the development 
pipeline (1). MAbs can treat diseases through neutralization, directly binding 
inflammatory molecules or eliciting the complement cascade though for the greatest 
efficacy the majority require FcR-mediated cell effector functions, including antibody 
dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis 
(ADCP).  
FcRIII (CD16) is the primary receptor that elicits cell-mediated immune 
responses and is a target for many mAbs (2-6). NK cells, macrophages and a subset of 
monocytes express CD16a as an integral membrane protein while neutrophils express 
the related glycosylphosphatidylinositol-anchored receptor CD16b (7). NK cells express 
only activating Fc Rs and can be activated through FcRs without priming, thus eliciting 
NK cell-mediated effector function represents an important therapeutic goal (8). Other 
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CD16+ cell types including monocytes, however, respond to antibody-coated targets 
and contribute to clearance (9). Monocytes appeared as the dominant effector cell for B 
cell removal and platelet phagocytosis with little contribution from NK or T cells (10, 11). 
Furthermore, increasing the strength of IgG binding by monocyte CD16a increases 
ADCC, indicating that increasing the strength of the monocyte CD16a–IgG interaction 
may lead to greater clinical efficacy (12). These results indicate that enhancing mAb 
affinity for CD16a expressed on monocytes/macrophage may lead to enhanced clinical 
efficacy. 
Monocytes are classified as classical, nonclassical and intermediate (13, 14). 
The classical CD14++,CD16- phenotype represents >80% of peripheral monocytes with 
nonclassical (CD14+, CD16++) and intermediate (CD14++, CD16+) monocytes 
accounting for the remainder. Monocytes also express the FcRs CD32a and CD64. 
Monocytes can differentiate into macrophages, dendritic cells and osteoclasts and 
adopt critical roles in tissue specific immune responses as well as wound healing (9, 
15). A recent study demonstrated that monocyte ADCC activity is exclusive to CD16+ 
nonclassical/intermediate monocytes (16). This manuscript showed that CD16 is 
indispensable for proper ADCC activity while CD32a contributes as well but to a lesser 
extent. 
The affinity between IgG and CD16a is dependent on polymorphisms and post-
translational modification. The CD16a V158 allele encodes a receptor with 4-5 fold 
greater affinity for IgG1 than the CD16a F158 allele (17). Interestingly, clinical efficacy 
of glycoengineered mAbs designed to bind CD16a with higher affinity is greater in V158 
homozygous individuals than F158 homozygotes, suggesting the affinity between IgG 
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and CD16a is directly correlated to clinical response (18, 19). Furthermore composition 
of the asparagine(N)-linked glycans also impacts the affinity of the CD16a-IgG 
interaction, though most studies focused on IgG N-glycan composition (2-6, 20-23).  
Recent in vitro studies indicated that CD16a N-glycan composition likewise affects 
binding to IgG (24-26). CD16a with an oligomannose-type N-glycan bound with greater 
affinity to IgG1 Fc than CD16a with complex-type N-glycans (21, 23, 27). Of the five 
CD16a N-glycans, the effect of N-glycan composition is primarily due to the modification 
at N162. Prior studies from our group identified the presence of minimally-processed 
endogenous CD16a glycoforms from primary NK cells and substantial donor-to-donor 
variability in processing at select sites (27, 52). Thus, post-translational modification 
plays a critical role in antibody-mediated functions, though little is known about how 
monocytes process CD16a. 
A description of FcR processing from monocytes is expected to define what 
receptor forms and affinities are present at the cell surface. Isolating receptors from the 
surface of primary human cells represents an enormous challenge due to the small 
amounts of receptor in the body. We recently described the analysis of CD16a N-
glycans from NK cells(52), however, monocytes represent a greater challenge. Despite 
the greater abundance of monocytes in the body compared to NK cells, monocytes 
express less CD16a than NK cells and in total contain about 20% of the CD16a 
compared to NK cells. 
CD16a and CD32a are highly modified molecules with five and two conserved N-
glycan sites, respectively. N-glycans represent the most prevalent post translational 
modification of excreted proteins and differences in composition result from differential 
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processing. In general, N-glycans are attached during translation and processed in the 
ER and Golgi into one of three main N-glycosylation types: oligomannose, hybrid or 
complex-type (reviewed in (28)). Late-stage processing enzymes in the trans-Golgi 
modify N-glycans with late stage “caps” including sialic acid or introduce branches 
making highly-processed complex-type N-glycans. Alternatively, some N-glycans 
escape the majority of the processing enzymes; these N-glycan types include 
oligomannose-type which are minimally processed and hybrid-type which experience 
late-stage processing on only part of the glycan. N-glycosylation heterogeneity is likely 
dictated by abundance of the remodeling enzymes as well as enzyme localization in the 
ER and Golgi network (29, 30). Cell-specific glycosylation differences have been 
described to be important in many biological processes, especially in development and 
the immune system (29, 31). Here we characterize the N-glycosylation profile of CD16a 




All materials were purchased from Millipore-Sigma unless otherwise noted. 
 
Experimental design 
This study was judged by Iowa State University’s institutional review to be 
exempt because the donors were de-identified, the only available donor information is 
shown Table 3.1. Biological replicates are represented by four single donors and six 
donors combined into two separate pools (MoA and MoB). Lysates from certain donors 
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were pooled and processed as a single sample due to low monocyte yields or 
unavailability of basic information typically available for other donors. Technical 
replicates were not possible since cell isolation from a single donor or donor pool only 
provided enough material to perform a single CD16a characterization.  
 
Protein expression 
Anti-CD16 (humanized Fc) 3g8, Anti-CD16 mouse 3g8, or Anti-CD16 mouse 3g8 
N297Q (heavy chain), which caused removal of N-glycosylation and was used for most 
of the immunoprecipitations in this study. Recombinant CD16a in HEK293F and 
HEK293S were transfected and purified as previously described (32). CD16a-Man9 and 
CD16a-Hybrid recombinant proteins were made by adding kifunensine and swainsonine 
to the culture, respectively (5 M). 
 
Surface Plasmon Resonance 




Leukocyte reduction system (LRS) filters were obtained from either LifeServe 
(Ames, Iowa) or the DeGowin Blood Center (University of Iowa, Iowa City) and 
processed within three hours of plasma or platelet donation. Cell isolations for NK cells 
were performed as described (27) and then frozen at -80°C except the RosetteSep 
Human Monocyte Enrichment Cocktail (Stem Cell Technologies) was used to isolate 
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purified monocytes through negative selection using Lymphoprep (Stem Cell 
Technologies).   
 
Flow Cytometry 
Non-specific antibody binding sites on 5 x 105 monocytes in 0.2 mL were blocked 
with 1 μl human serum. Then, anti-human CD14 (a mouse IgG2a, clone M5E2, 
BioLegend) and/or anti-human CD16 (3G8, mouse IgG1) was added to a final 
concentration of 2 g/ml and cells incubated on ice for 30 minutes. Cells were then 
washed 2x1 ml of phosphate-buffered saline plus 0.05% sodium azide; cells were 
pelleted during each wash by centrifugation at 600 x g for 8 min. The secondary 
antibodies anti-mIgG1 (RMG1-1 conjugated to allophycocyanin, BioLegend) and anti-
mIgG2a (RMG2a-62 conjugated to phycoerythin, BioLegend) were then added to a final 
concentration of 2 g/ml, mixed and cells incubated on ice for 30 minutes. Cells were 
then washed again as described above and fixed in 1% paraformaldehyde before flow 
cytometry analysis on the BD FACSanto (BD Biosciences) instrument. Gating of the 
monocyte population based on forward and side scattering was determined by 
excluding cell debris and smaller contaminating cells such as platelets and erythrocytes. 




Frozen cell pellets were thawed and immediately lysed using 40 L of lysis buffer 
((100 mM tris(hydroxymethyl)aminomethane, 100 mM sodium chloride, 5 mM 
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ethylenediamenetetraacetic acid, 5 mM oxidized glutathione, 10 M potassium 
ferricyanide, 1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride, 10 mg/mL 
dodecylmaltoside, pH 8.0) per 1x106 cells by repeated pipetting. Lysed cells were 
centrifuged for 20 min at 4400 x g in 4 °C to clarify the supernatant, which was saved 
separately, frozen overnight, thawed on ice and centrifuged again at 4400 x g for 20 min 
at 4 °C. Supernatent was sonicated for 1 min at full power in a bath sonicator, 100 μL 
protein G sepharose (GE healthcare) was added to the supernatant and incubated for 2 
h with end-over-end mixing. Resin was removed by centrifugation at 500 xg for 5 min, 
supernatant was moved to a new tube. Either 200 L Anti-CD16 (humanized Fc) 3g8, 
Anti-CD16 mouse 3g8, or Anti-CD16 mouse 3g8 N317Q covalently coupled to 
aldehyde-functionalized agarose beads (Thermo Fisher Scientific) was added, and 
incubated overnight with end-over-end mixing at 4 °C. Resin was pelleted by 
centrifugation at 500 x g for 5 min and supernatant was removed and stored as the “flow 
through” fraction. Resin was then washed 2x 0.5 ml with lysis buffer plus 0.5 M KCl, 2x 
0.5 ml lysis buffer, 2x 0.5 ml wash buffer (25 mM 3-(N-morpholino)propanesulfonic acid, 
100 mM sodium chloride) and 2x 0.5 ml 50 mM ammonium bicarbonate, pH 8.0. Resin 
was then moved to a micro biospin column (BioRad) and eluted with 5x 0.2 ml of 
(50:49.9:0.1  acetonitrile : water : trifluoroacetic acid) into 20 L 1 M ammonium 
bicarbonate. Samples were then pooled, frozen and lyophilized. Immunoprecipitation of 







The amount of recovered CD16a was estimated by western blot using 
recombinant CD16a as a standard. Western blots were performed as described (27). 
 
CD16a glycosidase treatment 
CD16a from primary NK cell and monocyte was immunoprecipitated as 
mentioned above except CD16a was not eluted after the wash steps and digestions 
were performed on CD16a bound to 3G8 agarose resin. Endo F1 was expressed using 
a plasmid provided by Dr. Kelley Moremen (University of Georgia) and isolated as 
mentioned previously (33). CD16a-loaded 3G8 agarose resin was diluted using 250 mM 
sodium phosphate buffer, pH 5.5. Endo F1 was added and incubated at 37 °C for 1.5 h. 
The reaction was stopped by boiling for 5 min in the presence of SDS-PAGE loading 
buffer (BioRad). PNGase F digestion was performed by following the manufacturer’s 
protocol (New England Biolab). Briefly, resin was boiled in presence of denaturing buffer 
before adding NP-40, reaction buffer and PNGaseF. The reaction was incubated at 37 
°C for 4 h and was stopped by boiling the samples in presence of SDS-PAGE gel 
loading buffer. Soluble CD16a (sCD16a) from NK cell and monocytes was obtained by 
incubating isolated NK cell and monocytes at 37°C for 1 h at a cell density of 10×106 
cells/ml in RPMI 1640 (Thermo Scientific) medium supplemented with 1% fetal bovine 
serum (VWR), 1 g/ml phorbol 12-myristate 13-acetate and 1 mM 4-(2-aminoethyl) 
benzenesulfonyl fluoride (Millipore Sigma). The cells were removed by centrifugation 
and the supernatant frozen until sCD16a was immunoprecipitated using the method 
described above. Negative controls for each reaction were treated as digested samples 
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except enzymes were not added. Recombinant CD16a (250 ng) expressed in HEK293F 
or HEK293S served as a positive control. Boiled samples were directly loaded on 12% 
SDS-PAGE gels and analyzed using antiCD16 western blot.  
 
CD16a proteolysis 
CD16a was resuspended in 100 l of 50 mM ammonium bicarbonate, pH 8.0 and 
heat denatured at 90 °C for 5 min and cooled on ice. A 1:40 (w:w) ratio of chymotrypsin 
and 1:30 (w:w) of Glu-C (Promega) was added and the solution incubated at 25 °C 
overnight. Fresh chymotrypsin and Glu-C was added and the solutions incubated for 3 
h. Chymotrypsin is specific for FYW with lower specificity for ML while Glu-C is specific 
for E. Both enzymes cut at the C-terminal of the mentioned amino acid residue. 
Following proteolysis, dithiothreitol was added to a final concentration of 5 mM and the 
solution incubated for 1 h at 37 °C. Iodacetamide was then added to a final 
concentration of 15 mM and the solution incubated in the dark at RT for 1 h. The sample 
was then centrifuged for 2 min at 9600 x g, the supernatant transferred to a new tube, 
frozen at -80 °C and lyophilized. Lyophilized samples were resuspended in 10 l of 
water and then glycopeptides were enriched using the ProteoExtract Glycopeptide 
Enrichment Kit following the manufacturer’s guidelines to separate peptides from 
glycopeptides. Isolated glycopeptides were then frozen, lyophilized, resuspended in a 
solution containing 5% acetonitrile and 0.1% formic acid before MS analysis. 
Peptides were desalted using ethyl acetate: a glass tube was washed with 200 
ml ethyl acetate. Water saturated ethyl acetate was made by mixing 5 ml ethyl acetate 
with 625 l water in the washed glass tube. 1 ml of the upper phase was added per 100 
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l sample. Samples were vortexed for 1 min, centrifuged for 12,500 x g and the upper 
layer was removed and discarded. This washing procedure was repeated 3 times. 
Residual ethyl acetate was removed from the top under a nitrogen stream. Isolated 
peptides were then frozen, lyophilized, resuspended in a solution containing 5% 
acetonitrile and 0.1% formic acid in water prior to MS analysis (34). 
 
Mass Spectrometry 
Sample (5 L) in buffer A (5% acetonitrile, 94.9% water and 0.1 % trifluoroacetic 
acid) was loaded onto a 75 mm x 20 cm column packed with C18 Zorbax resin (3 or 5 
m) equipped with a pulled glass emitter using an EASY-nLC 1200 nanopump (Thermo 
Fisher Scientific) in line with a Q-exactive Hybrid Quadrupole-Orbitrap Mass 
Spectrometer (Thermo Fisher Scientific). The column was briefly washed with buffer A. 
Analytes were eluted at flow rate of 300 nl/min with an increasing linear gradient of 
buffer B (99.89% acetonitrile, 0.01% formic acid, 0.1% trifluoroacetic acid) from 0 to 
35% over 60 min. Buffer B was then increased to 70% for 10 min and then 100% for 10 
more min before returning to 0% B. In between experimental samples, buffer A (20 l) 
was loaded on to the column and eluted as a “blank”. A peak observed at 600 m/z in the 
MS2 spectra represents carryover from a calibration standard. 
 
Data Analysis 
Raw data files were initially analyzed with Byonic (Protein Metrics). The search 
parameters included Cleavage site (FYWEL), Cleavage side (C-terminal), Digestion 
specificity (Semi specific (slow)), Missed cleavages (2), Precursor mass tolerance (5 
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ppm), Fragment mass tolerance ( 0.05 Dalton), Recalibration (lock mass) (none), 
maximum precursor mass (5,000), Precursor and mass charge assignments (Compute 
from MS1), Maximum # of precursors per scan (10), smoothing width (0.01 m/z) and the 
following modifications included (in addition to N- and O-glycan databases): 
Carbamidomethyl / +57.021464 @ C | fixed; Deamidated / +0.984016 @ N | common1; 
Acetyl / +42.010565 @ Protein N-term | rare1; Phospho / +79.966331 @ C, D, H, K, R, 
S, T,Y | common2; HexNAc / +203.079373 @ N,S,T | common1. Hits were then 
manually validated and additional peaks not identified by Byonic were found. 
Glycopeptide annotations were made in Glycoworkbench Version 2.1 (35). Annotated 
MS2s for each species are shown in a Supplemental PDF and a recent characterization 
of this purification and analysis strategy using NK cells (52). Species without clear MS2 
spectra were assigned if they showed retention times and predictable differences from 
known species (ie 162.05 Da). N-glycan structures indicate composition only without 
linkage information elucidated. Analyte intensities were measured from MS1 spectra 
using scripts in R based on retention time windows defined for each species (52). This 
approach measured the intensity of as many as seven isotopologue peaks for each 
glycopeptide. Isobaric species were not differentiated. 
 
Donor genotyping 
Blood retained in the tubing of the apheresis filters (~50 L) was centrifuged at 
10,000 x g for 10 min and the cell pellet and serum fractions were stored separately at -
80 °C. The RNA from the cell pellet was isolated using the Trizol Reagent as directed by 
manufacturer (Thermo Fisher Scientific). cDNA was prepared from the isolated RNA 
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using the High Capacity RNA to cDNA as directed by the manufacturer (Thermo Fisher 
Scientific). The full FCGR3A ORF including region coding for amino acid 158 in the final 
protein was then amplified using AccuPrime PFX with forward (5’-
CAGTGTGGCATCATGTGGCAG-3’) and reverse (5’-TTTGTCTTGAGGGTCCTTTCT-
3’) primers. Resulting DNA was purified with a Gel Extraction Kit (Qiagen) and 
submitted for Sanger Sequencing at the Iowa State Sequencing Facility. 
 
Results 
Apheresis filters entrap monocytes 
We isolated primary human monocytes from apheresis filters following plasma or 
platelet donation to define specific features of CD16a expressed by monocytes. 
Apheresis filters provided an average of 4 x 108 monocytes per donor following negative 
selection (Table 3.1). Sequencing cDNA from each donor’s leukocytes revealed that the 
majority of donors expressed both the V158 and F158 alleles, as expected (Table 3.1). 
Flow cytometry indicated a high percentage of cells (82.3 - 97.6%) expressed CD14 in 
the expected proportion of “classical” CD14+ CD16dim to “non-classical” CD14dim CD16+ 
monocytes (83-85% and 15-17%, respectively; (13, 14, 36)). Individual donors also 
displayed variation in the level of CD16 staining for the CD16+ monocytes. 
  
CD16a N-glycan modifications 
Previous studies indicated CD16a N-glycosylation composition affects binding to 
IgG1, however it was unknown if forms that bind with high affinity in vitro are present on 
circulating monocytes (23, 27). We analyzed six monocyte CD16a samples, four 
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isolated from single donors and two as pools of three donors (Table 3.1). Data from 
these donors revealed 133 unique CD16a glycopeptides that contained a total of 77 
unique N-glycans (Table 3.2). Our analysis revealed only N-glycan modifications. We 
also characterized non-modified peptides for a total of 84% coverage of the peptide 
backbone (Figure 3.1C).  
 
Table 3.1. Donor information 











MoA (pool)        
Mo01 n.d. n.d. n.d. n.d. 6/9/2017 200 V/F 
Mo03 n.d. n.d. n.d. n.d. 6/9/2017 329 V/F 
Mo05 n.d. n.d. n.d. n.d. 6/9/2017 351 V/V 
        
MoB (pool)        
Mo06-i n.d. n.d. n.d. n.d. 6/9/2017 580 V/F 
Mo06-ii F 73 AB + 3/16/2017 280 F/F 
Mo06-iii F 35 AB + 4/6/2017 139 V/F 
        
Mo02 F 17 B + 6/9/2017 200 V/V 
Mo04 n.d. n.d. n.d. n.d. 6/9/2017 362 F/F 
Mo11 M 61 A + 6/8/2018 406 V/F 
Mo13 F 40 O + 8/28/2018 303 F/F 
Mo15 M 27 O + 8/28/2018 588 V/F 





Figure 3.1. CD16a N-glycosylation composition varies by site and donor on monocytes. A. CD16a 
contains 5 N-glycosylation sites on the extracellular domain. These sites are modeled from the most 
abundant forms found on monocytes; the ribbon diagram and surface rendering are based on known 
structures of CD16a determined by X-ray crystallography. Carbohydrate residues are modeled as 
cartoons using the SNFG convention and roughly scaled to size (45). B. The relative abundance of each 
N-glycan type for the four individual donors and two donor pools as specified in Table 3.1. n.a. – not 
applicable. C. ESI-MS/MS identified peptides and glycopeptides covering 84% of the CD16a sequence. 
Glycosylated Asn residues are shown in red. The V/F158 amino acid residue is labeled in blue. 
 
Subtle donor-dependent variation in N162-glycosylation 
The N162 glycopeptides also contain F158 or V158, linking the CD16a allele with 
processing at N162. The glycopeptides identified for each donor matched those 
expected based on cDNA sequencing (Table 3.2). The N162 glycopeptides produced 
ions with relatively high intensity and high quality MS2s for most species as shown in 
Figure 3.2. HCD fragmented ions confirm composition of the ion, in particular through 
monosaccharide species specific for sialic acid (292.10 Da or 274.09 Da (-H2O)) and 
72 
 
HexNAc (204.09 Da), disaccharide species including HexNAc-Hexose (366.14 Da), and 
trisaccharide species including HexNAc-Hexose-Sialic acid (657.24 Da). A peak 
corresponding to the peptide + HexNAc is a common diagnostic glycopeptide and also 
one of the most intense as noted previously (43). Most of these ions contain a 
deoxyhexose residue and fragments corresponding to the peptide + HexNAc + 
deoxyhexose and are likely core fucosylated, though we cannot eliminate the possibility 
of branch fucosylation because isomeric species were likely not separated during 
chromatography. 
 
Table 3.2. Glycopeptides identified in this study. 
 

















1 KCQGAYSPEDNSTQW 6 2 5 8 n.d. 2 11 
2         SPEDNSTQW 3 3 n.d. 7 n.d. n.d. 9 
N45 
 
1    FHNE 17 16 10 14 11 15 21 
2    FHNESLISSQASSY 5 18 18 8 3 10 28 
N74 1 RCQTNLSTLSDPVQLE 16 7 5 3 4 3 24 
N162 
(V158) 
1 CRGLVGSKNVSSE 10 20 8 15 n.a. 6 21 
N162 
(F158) 
2 GSKNVSSE n.a. 1 6 2 2 4 6 
N169 1 TVNITITQGL 5 7 3 2 2 2 9 
 
2             TVNITITQGLA n.d. 1 2 3 2 n.d. 4 
 
 
total unique glycans:  77   total glycopeptides: 133 
n.a = not applicable        





The predominant N162 glycans, averaged across all donors and allotypes, are 
summarized in Figure 3.2 with a core-fucosylated monosialylated complex-type N-
glycan representing the most abundant species, though other forms also appear 
including complex-type biantennary, triantennary and hybrid-types. Other low abundant 
species include tetrantennery complex-type as well oligomannose-type N-glycans. 
Interestingly, four datasets revealed small amounts of oligomannose-type N162-glycans 
(<10%). Overall, we determined that the N162-(F158)-glycan from these six datasets 
was 99.7% complex-type and 0.3% hybrid-type while the N162-(V158)-glycan was 
88.9% complex-type, 7.1% hybrid-type and 3.9% oligomannose-type N-glycans. 
 
CD16a V158 with hybrid or oligomannose-type N162-glycans exhibits greater 
affinity for IgG1 Fc 
The appearance of under-processed N162 glycoforms from some donors is 
noteworthy because CD16a V158 with oligomannose-type N162 glycans binds IgG1 Fc 
with greater affinity in vitro, suggesting the monocytes from some donors express 
CD16a with enhanced affinity (20, 21, 23, 27). However, it is unclear how hybrid-type N-
glycans impact affinity or if the CD16a F158 allotype displays a similar enhancement. 
SPR binding studies between IgG1 Fc and CD16a expressing complex-type (CT), Man9 
or hybrid-type N-glycans indicate an affinity enhancement when CD16a has Man9 or 
hybrid-type as compared to complex-type (Table 3.3). These results are comparable to 
previous measurements from our lab, though the absolute difference in enhancement 
due to the presence of a oligomannose-type N-glycans is reduced (20, 21, 23, 27). 
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Likewise, these are consistent with previous data showing the negative impact of Fc 
fucosylation on affinity for all three V158 glycoforms. In this experiment, the hybrid-type 
N-glycans increased CD16a V158 binding to IgG1 Fc by 1.4-2.3 fold, while 
oligomannose N-glycans increased affinity by 2.5-2.9 fold as compared to CD16a V158-
CT. As expected, CD16a F158 bound IgG1 Fc with lower affinity than the V158 allotype 
(17). Surprisingly, receptor glycan composition did not appear to impact binding 
affinities of the CD16a F158 allotype. 
 
 
Figure 3.2. The CD16a N162-glycan is predominantly a monosialylated biantennary complex-type with 
some hybrid/oligomannose. The relative abundance represents the averages of each species from 
datasets originating from individual donors and donor pools and the pie charts represent the average 
abundance of each N-glycan type. A. Relative abundance of F158 glycopeptides (1 and 7). B. Relative 
abundance of glycopeptides for a single V158-specific peptide. C. A representative MS2 spectrum for 
most abundant N162 F158 glycopeptide. D. A representative MS2 spectrum for most abundant N162 
V158 glycopeptide. Cartoons indicate one possible glycan configuration consistent with the composition, 




Table 3.3. Equilibrium dissociation constants (KD) from SPR analysis of the CD16a and IgG1 Fc 
interaction (Errors represent errors of fit to the Langmuir binding isotherm; this experiment is 
representative of three independent experiments). 
 
IgG1 Fc G0F 
 
IgG1 Fc G0 
Receptor KD (nM) error   KD (nM) error 
CD16a V158-CT 500 30 
 
100 10 
CD16a V158-Man9 170 20 
 
40 10 
CD16a V158-Hybrid 220 20 
 
70 10 
CD16a F158-CT 1500 100 
 
240 40 
CD16a F158-Man9 1300 200 
 
200 70 




Restricted processing and variability at N45 
N45 glycosylation shows the most restricted processing and greatest variability 
compared to the other four CD16a N-glycosylation sites. Two N45 peptides contained 
the N45-glycan (Table 3.2), N45 peptide 1 is the expected degradation product and 
peptide 2 is the product of a missed Glu-C cleavage. A hybrid-type N-glycan with a 
sialic acid residue, three mannose residues that lacks fucosylation is the most 
predominant species found in all six datasets (Figure 3.3). N45 glycan exhibited 
substantial variability between donors with a range of 1.0 - 50.2% complex types, 36.0 - 
64.0% hybrid types and 1.7 - 58.8% for oligomannose types. MS2 fragmentation of 
hybrid-type N-glycan with one fucose and one sialic acid as well as an oligomannose-
type glycan are illustrated in Figure 3.3. Diagnostic fragments in the MS2 spectra 
include hexose (163.06 Da), HexNAc (204.09 Da) and HexNAc + hexose (366.14 Da) 





Figure 3.3. N-glycosylation at N45 shows restricted processing with mostly hybrid and oligomannose N-
glycans. A. Schematic showing the location of N45. B. Charts showing the average abundance of each 
N-glycan type. C. The most abundant N45-glycan species identified, ranked according to average 
abundance. The intensities of N45 glycopeptides 1 and 2 were combined for this analysis. MS2 
fragmentation for the most abundant hybrid (D.) and oligomannose-type N-glycans(E.). 
 
Extensive modification with LacNAc units at N38 and N74 
N-glycans at the N38 and N74 sites displayed exclusively highly processed 
complex-type N-glycans (Figure 3.4). Repeats of a hexose-HexNAc moiety define the 
predominant features of these species, though sialic acids and fucosylation are also 
present. The most intense ions differed by the number of hexose-HexNAc units and 
contained 2-5 sialic acids. Analysis of the monoisotopic peaks from the parent ions in 
the MS1 dimension provided differentiation of species to determine the presence of two 
77 
 
fucose residues versus one sialic, thus there are at most 4 sialic acids at these two 
sites. Due to the large size of these ions and overall lower intensity compared to the 
N45 and N162 glycopeptides, MS2 fragmentation proved much weaker for these 
species and only showed the diagnostic peptide + GlcNAc ion for N38 and N74 (data 
not shown).  
 
Figure 3.4. Processing of the N38, N74 and N169 N-glycans. N-glycans at N38 (A.) and N74 (B.) are 
exclusively highly processed forms with LacNAc repeats. C. N-glycosylation at N169 is predominantly a 
complex-type biantennary form with some tetra-antennary complex-types as determined by combining 
intensities of peptide 1 and 2.  
 
N169-glycans are predominantly complex-type 
Complex-type N-glycans exclusively occupied N169 in all donors (Figure 3.1). A 
complex-type biantennary with one fucose and one sialic acid was the most 
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predominant N169-glycan, the same predominant form found at N162 (Figure 3.2). The 
ADAM17 cleaved peptide (N169 peptide 2) was identified but at a much lower intensity 
when compared to the expected Glu-C and chymotrypsin peptide (N169 peptide 1) 
(Table 3.2), though this may result from non-specific proteolysis during peptide 
purification. 
 
Monocytes process CD32a differently than CD16a 
Monocytes also express CD32a that contains two N-glycosylation sites and 
glycan profiles that are unlike CD16a. Two pooled datasets (MoA and MoB) included 
CD32a peptides because we purified CD16a from these samples using 3G8 (a mouse 
IgG1) that contained an Fc N297-glycan that captured CD32a, unlike the single-donor 
datasets purified over immobilized 3G8 without Fc N-glycosylation that didn’t bind 
CD32a (44). Analysis of the peptides from these datasets provided 61% sequence 
coverage of CD32a (Figure 3.5). Of these two datasets, MoB produced N64 and N145 
N-glycopeptide ions with high intensity in the MS1 dimension and high quality MS2 
spectra (Figure 3.5). N-glycans at these sites were predominantly complex-type 
biantennary species with a core fucose residue and two sialic acids. MS2 fragmentation 
confirmed these assignments (Figure 3.5E and F). MoA provided only a single N64 
glycopeptide that matched the predominant N64 species from MoB. Similarly, the most 
abundant N145 species from both datasets proved identical. The MoA dataset included 
7% oligomannose forms and 2% hybrid forms unlike the MoB dataset that revealed no 
oligomannose forms and 17% hybrid forms (data not shown). These data indicate the 
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possibility for a surprising degree of variability at the N145 site and stark differences in 
processing compared to CD16a from the same donor pools.  
 
Figure 3.5. Purified CD32a contains predominantly complex-type biantennary N-glycans. A. CD32a 
contains 2 N-glycosylation sites on the extracellular domain. These sites are modeled from the most 
abundant forms found on monocytes; the ribbon diagram and surface rendering are based on known 
structures of CD32a determined by X-ray crystallography. The most abundant N-glycans at N64 (B) and 
N145 (C). D. ESI-MS/MS identified peptides and glycopeptides covering 61% of the CD32a sequence. 
Glycosylated Asn residues are shown in red. Representative MS2 spectra for the most abundant N-





 We defined the composition of CD16a N-glycans isolated using primary human 
monocytes recovered from apheresis filters. These data indicated that location impacted 
CD16a N-glycan composition to a greater degree than other variables including donor 
age, genotype, etc. (Figure 3.1B, Table 3.2). In general, the CD16a N38 and N74-
glycans are exclusively of a highly-processed complex-type with N-acetyllactosamine 
repeats, N169 are complex-type, N162 are predominantly complex-type with some less-
processed forms present in some donors, and N45 contains a mixture of complex, 
hybrid and oligomannose types. This analysis reports increased sensitivity compared to 
the previous analysis of CD16a from the NK cells of single donors reported by our group 
(52). Though monocytes are more abundant in the peripheral blood of most donors, 
monocytes express less CD16a than a typical NK cell.  
 The initial comparison of CD16a from monocytes and NK cells revealed 
differences that are attributable to N-glycan composition (data not shown). Surprisingly, 
EndoF1 digested NK cell CD16a but not monocyte CD16a. This is likely due to 
differences in N45-glycan composition; monocyte N45 contains a much higher 
proportion of smaller hybrid types that lack a fourth mannose residue (likely the 1-
3Man on the 1-6Man branch) that is required for EndoF1 activity (45) and is found on 
the NK cell CD16a N45 N-glycans (52).  
Restricted processing at N45 is not unique to monocyte CD16a (Figure 3.2). NK 
cell CD16a N-glycosylation displays more restricted processing than recombinant 
CD16a expressed in HEK293F cells (27). A recent study found CD16a N45 on NK cells 
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displays predominantly hybrid-type (52) and hardly any oligomannose forms unlike 
CD16a from monocytes reported here which has mostly hybrid and oligomannose-type. 
Furthermore, CD16b, the highly related FcR expressed by neutrophils contains 
predominantly oligomannose and minimal hybrid-type N45-glycans unlike CD16a from 
both NK cells and monocytes (43, 46). CD16 N45 N-glycosylation processing can be 
summarized as NK cell > monocyte > neutrophil. NMR and molecular dynamics 
simulations indicate the CD16 N45 N-glycan makes intramolecular contacts with the 
polypeptide leading to decreased mobility of the N-glycan (21, 22). Thus, restricted 
processing of N45 likely results from carbohydrate-polypeptide contacts that reduce 
accessibility to glycosyl transferases and glycosidases. 
CD16 N162 processing on NK cells varied by donor though neutrophils or 
monocytes expressed receptor with much less variability at this site (Figure 3.2; (43, 
46,52)). Processing at the remaining three sites is more directly comparable between 
the three cells types. Gene microarray data indicate that monocytes express the 
biosynthetic machinery for multiantennary branching of N-glycans including N-
acetyllactosamine structures (47). MGAT5 catalyzes addition of the fourth branch 
GlcNAc residue to the 6-OH of the 1-6Man residue of a triantennary complex-type N-
glycan, providing the likely site for LacNAc polymerization (48). Interestingly, Galectin 3 
binds poly-LacNAc motifs on N-glycans and regulates T cell receptor clustering and cell 
activation (49, 50). It remains unclear if CD16a LacNAc motifs on NK cells, monocytes 
or neutrophils adopt similar roles. 
This cell isolation and purification strategy proved sufficient to determine the 
unique distribution of N-glycoforms at each of the five CD16a N-glycan sites and 
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provided a comparable analysis of CD32a from the same cells. Interestingly, the two N-
glycosylation sites on CD32a, N64 and N145, were predominantly complex-type 
biantennary with two sialic acids and one fucose, unlike any of the major forms on the 
five CD16a sites. Thus, these monocytes processed CD16a and CD32a N-glycosylation 
differently. Because the purification targeted CD16a, it is possible that stronger binding 
CD32a glycoforms preferentially bound the mIgG1 and are thus enriched in these 
datasets, however this appears unlikely because binding differences of CD32a 
glycoforms for human IgG1 Fc were not identified (23). Saggu and coworkers recently 
characterized CD32a N-glycans purified from neutrophils and identified the identical 
predominant N64-glycan but a high percentage of under-processed N145 glycans 
including oligomannose and hybrid-types (44). These authors found sialylated CD32a 
interacted with Mac1 which downregulated CD32a activity implicating CD32a N-
glycosylation as functionally relevant mediators of neutrophil activation. Interestingly, 
monocytes reportedly downregulate Mac-1 expression after incubation with IgG, CD32a 
N-glycans may perform a comparable role on monocytes (51). 
In summary, these data provide insight into how an individual donor modifies 
individual N-glycosylation sites on two different FcRs recovered from a single cell type. 
Differential modifications potentially provide an individual with the ability to modify the 
activation threshold by controlling receptor affinity, and this approach affords the ability 
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Abstract 
CD16a/Fc γ receptor IIIa is the most abundant antibody Fc receptor expressed 
on human natural killer(NK) cells and activates a protective cytotoxic response following 
engagement with antibody clustered on the surface of a pathogen or diseased tissue. 
Therapeutic monoclonal antibodies(mAbs) with greater Fc-mediated affinity for CD16a 
show superior therapeutic outcome, however, one significant factor that promotes 
antibody-CD16a interactions, the asparagine-linked carbohydrates(N-glycans), remains 
undefined. Here, we purified CD16a from the primary NK cells of three donors and 
identified a large proportion of hybrid(22%) and oligomannose N-glycans(23%). These 
proportions indicated restricted N-glycan processing and were unlike those of the 
recombinant CD16a forms, which have predominantly complex-type N-glycans(82%). 
Tethering recombinant CD16a to the membrane by including the transmembrane and 
intracellular domains and via co-expression with the Fc ε receptor –chain in HEK293F 
cells was expected to produce N-glycoforms similar to NK cell-derived CD16a but 
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yielded N-glycoforms different from NK cell-derived CD16a and recombinant soluble 
CD16a. Of note, these differences in CD16a N-glycan composition affected antibody 
binding: CD16a with oligomannose N-glycans bound IgG1 Fc with 12-fold greater 
affinity than did CD16a having primarily complex-type and highly branched N-glycans. 
The changes in binding activity mirrored changes in NMR spectra of the two CD16a 
glycoforms, indicating that CD16a glycan composition also affects the glycoprotein’s 
structure. These results indicated that CD16a from primary human NK cells is 
compositionally, and likely also functionally, distinct from commonly used recombinant 
forms. Furthermore, our study provides critical evidence that cell lineage determines 
CD16a N-glycan composition and antibody binding affinity. 
 
Introduction 
Antibodies activate a diverse set of protective responses following the recognition 
of a previously-encountered epitope. Therapeutic monoclonal antibodies (mAbs) 
circumvent prior exposure to induce a protective response against diseased tissue by 
eliciting the same protective mechanisms, including antibody-dependent cell mediated 
cytotoxicity (ADCC) through binding Fc  receptors (FcRs), and represent a major drug 
class worth tens of billions of dollars each year in global sales. MAbs are predominantly 
built from immunoglobulin G (IgG) and a large proportion bind FcRs expressed on a 
range of leukocytes to initiate target destruction. However, very little is known about the 
composition of FcRs from native leukocytes and how this composition affects IgG 
binding and thus treatment efficacy. 
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ADCC is predominantly performed by natural killer (NK) cells (1), cytolytic 
lymphocytes present as 1-6% of circulating leukocytes (2,3) that express 
FcRIIIa/CD16a as the predominant FcR. The activating role of CD16a in ADCC by NK 
cells is well established (1). Indeed, investigations of rituximab, trastuzumab and 
cetuximab therapeutics demonstrated the importance of CD16a on NK cells for success 
(4). 
Improved therapeutic mAb efficacy can be achieved by enhancing the mAb-
CD16a interaction. In-vitro binding studies demonstrated the less common CD16a V158 
allotype binds IgG1 with ~5 fold greater affinity compared to CD16a F158 (5). 
Furthermore, increased binding leads to an increased NK cell response and increased 
ADCC (6-9). Current advances in mAb therapy are targeting optimization of NK cell 
ADCC activity by Fc glycoengineering to improve CD16a binding (4). These efforts 
include targeted modifications to the asparagine-linked carbohydrate (N-glycan) 
attached to N297 of the IgG1 heavy chain (9,11). A glycoengineered mAb performed 
better in the clinic when compared to a non-optimized version (4,12). 
N-glycans contribute to protein function and are targets for new therapies or 
enhancing existing therapies. N-glycan processing occurs during protein secretion. The 
types and extent of modifications are not template driven, thus, it is not currently 
possible to predict N-glycan composition from DNA sequence information. Following the 
en bloc transfer of a 14-residue precursor N-glycan as directed by the presence of a N-
X-S/T sequon where X is any residue except proline, the glycoprotein associates with 
protein-folding specific chaperones, and if properly folded, continues through the ER 
and Golgi-mediated secretory pathway to encounter remodeling glycosylhydrolase and 
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glycosyltransferase enzymes (Figure 4.1). Though many factors contributing to N-
glycan composition on any given protein remain undefined, it is generally believed that 
modifying enzyme expression, protein structure and the presence or absence of a 
membrane anchor affect N-glycan composition in the secreted protein (13). N-glycans 
that experience minimal processing emerge from the cell as oligomannose forms 
(Figure 4.1B). More highly processed N-glycans may also include hybrid forms and the 
predominant complex-types found on cell surfaces and circulatory serum proteins. 
Additional to folding, N-glycans promote secretion, protection against proteolysis, 
reduce antigenicity, extended serum half-life, and contribute specific epitopes for 
receptor binding as well as impact protein structure and function (14-16). 
 
Figure 4.1 (AWB). Membrane-anchored CD16a binds IgG antibodies. A. CD16a (orange ribbon) contains 
five potential N-glycosylation sites in the extracellular domains (orange spheres). B. N-glycan processing 
occurs in the ER and Golgi following transfer of a large glycan en bloc to the protein and produces 
oligomannose, hybrid and complex-type N-glycans. Individual carbohydrate residues are colored 
according to the SNFG convention (14). 
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The CD16a sequence encodes five N-glycosylation sites, though little is known 
about either the N-glycan composition or how CD16a N-glycans impact function. Edberg 
and Kimberly reported that NK cell CD16a contained a high degree of oligomannose-
type N-glycans using immobilized lectin chromatography and found little evidence for 
complex or hybrid types (17). This characterization was in stark contrast to later mass 
spectrometry-based reports on the glycosylation of recombinant CD16A which identified 
predominantly complex-types with low percentages (2-5%) of oligomannose N-glycans 
(18-21), however, these recombinant expressions did not include the membrane anchor 
and intracellular domains, as well as the coexpressed Fc  receptor - or CD3 - chains 
that may influence N-glycan processing. It is well known that N-glycan composition can 
influence protein function (15,22-24), with some evidence indicating composition might 
affect the antibody-binding function of CD16a (21). Thus, the in vitro analyses of 
monoclonal antibody binding by CD16a should include proper N-glycoforms for 
representative results. At this point, there has not been a report on the high-resolution 
N-glycan composition of CD16a from primary human leukocytes. 
Access to a sufficient quantity of primary human tissue represents a significant 
barrier to high-resolution composition studies because CD16a is expressed by a limited 
subset of leukocytes, including natural killer cells and CD16a+ monocytes that constitute 
1-6% and 0.4-2.4% of circulating leukocytes, respectively (3,25). We predict that it 
would require as much as 1.25 L of human blood to recover a minimum of 100 x106 
natural killer cells and 1 g of CD16a from a single donor to provide sufficient material 
for characterization. It is untenable to harvest one-quarter or more of a donor’s blood 
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volume for obvious reasons. The adoption of apheresis systems by blood donation 
centers to collect plasma, platelets and other blood components provides a valuable 
source of viable primary human lymphocytes from peripheral blood through leukocyte 
reduction system (LRS) filters that are normally discarded following donation (26). In 
this manuscript we describe a method to purify CD16a from primary human NK cells 
from a single donor to analyze N-glycan composition. 
 
Results 
NK cell isolation and CD16 purification 
Light scattering of isolated NK cells combined with CD56 and CD16 staining 
assessed by flow cytometry revealed >90% cell purity, >87% viability and a high degree 
of CD16 expression (Figure 4.2). A blot of NK cell lysate probed with an anti-CD16 
antibody showed a band from 53-59 kDa (Figure 4.2C). Despite differences in CD16 
staining intensity measured from more than a dozen donors, NK cell lysate repeatedly 
showed indistinguishable CD16 migration characteristics (data not shown). The mobility 
of the NK cell CD16 band in a sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) experiment increased following digestion with PNGaseF, 
an enzyme that specifically removes N-glycans. However, the resulting two bands at 
~33 kDa are still larger than expected for the 27 kDa CD16a polypeptide (Figure 4.2C). 
This treatment indicates that N-glycans retard CD16 mobility in a polyacrylamide gel. 
The CD16 identified here is consistent with CD16 from multiple previous reports based 




Figure 4.2 (JTR/KRP). Representative NK cell isolation and CD16a purification. A.  Light scattering and B. 
double-antibody staining of negatively-selected NK cells. Isotype and negative staining controls are shown 
in Figure S1. C. Anti-CD16 western blot of PNGase F-digested CD16a shows an increase in mobility 
following N-glycan removal. D. Anti-CD16 western blot of CD16a purification from an NK cell lysate 
compared with recombinant CD16a truncated at the transmembrane domain (HEK293F). 
 
 A monoclonal anti-CD16 mouse IgG1 antibody, 3G8 (31), is widely used for flow 
cytometry but not for western blot applications because CD16 denaturation destroys the 
epitope (data not shown). Thus, 3G8 is a good candidate to precipitate folded and 
processed CD16 from cell lysates at a preparative scale. Our purification scheme first 
lyses NK cells in detergent, followed by incubation with protein G resin to remove IgG 
that may obscure the CD16 epitope recognized by the 3G8 antibody, adsorption to a 
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3G8-agarose resin, extensive washing to remove material that weakly interacts with the 
resin, and finally elution with 45:55:0.1 water:ACN:TFA. This procedure showed clear 
depletion of CD16 from the NK cell lysate and enrichment in the elution fraction with 
recovery of ~1 g CD16 / donor (Figure 4.2D). 
 
CD16a validation with ESI-MS/MS 
The observed mobility of CD16 from primary human NK cells in SDS-PAGE gels 
is similar to previous reports and likely represents similar material, though peptide 
sequencing or other comparable techniques were not previously applied for validation. 
Thus, we applied high-resolution peptide sequencing to verify the immunoprecipitated 
material. Purified and trypsin-digested CD16a from a single donor’s NK cells generated 
multiple polypeptide fragments in an HPLC(C18)-ESI-MS/MS experiment that fit with 
high confidence to 47% of the CD16a sequence (Figure 4.3). One peptide revealed this 
donor expressed the predominant CD16a F158 allele (Figure 4.3D). The donor allotype 
was also confirmed by cDNA sequencing (data not shown). Peptides containing 
predicted CD16a N-glycosylation sites, transmembrane or intracellular regions were not 
detected but the observed peptides were enough to confirm CD16a identity and found 
no other peptides. It is possible that the immunoprecipitated material includes low levels 
of contaminating proteins. To address this potential shortcoming we analyzed PNGase-
F treated peptides from a single donor using HPLC(C18)-ESI-MS/MS. This sample 
contained the Fc  receptor -chain and the ubiquitous contaminant keratin from human 
hair and skin cells. Again, CD16a accounted for a majority of the identified peptides. 
Surprisingly, human actin and myosin coeluted with CD16a, as well as trace amounts of 
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trypsin and the IgG1 heavy chain. With the exception of the IgG1 heavy chain that 
leached from the immunoprecipitation column, none of the identified proteins were N-
glycoproteins. These results indicate that the PNGase-F treatment of the elution fraction 
will produce only CD16a N-glycans from NK cells if the immunoprecipitation antibody is 
treated to remove N-glycans prior to immobilization. 
 
Figure 4.3 (JTR). ESI-MS/MS analysis identifies only CD16a following immunoprecipitation from NK 
cells. A. Peptides identified are shown with a blue bar under the CD16a sequence. Expected trypsin 
cleavage sites are indicated with a vertical line and N-glycosylation sites are denoted with a red “N.” B-D. 





N-glycan analysis of CD16a from primary human NK cells  
We isolated peripheral NK cells from three male donors ranging in age from 66-
78 to characterize N-glycan composition; blood remaining in the LRS filter after 
apheresis provided genetic material to determine the donor’s CD16a allotype (Table 
4.1, data not shown). Following cell lysis, CD16a immunoprecipitation utilized EndoS-
treated 3G8 antibody to eliminate potential contamination with antibody N-glycans (data 
not shown). Analysis of procainamide-modified CD16a N-glycans by hydrophilic 
interaction liquid chromatography(HILIC)-ESI-MS showed a strong correlation between 
N-glycan elution time and N-glycan mass (Figure 4.4). We identified 33, 27 and 19 
CD16a N-glycans from Donors 1, 2 and 3, respectively, with an average mass error of 
0.0010 Da for the three datasets (data not shown). The CD16a glycans contained 
minimally processed forms including a high percentage of oligomannose (23%) and 
hybrid types (22%; Figure 4.5). Of the remaining complex-type N-glycans (55%), 
biantennary forms comprised more than half of the complex-type species (51%). CD16a 
N-glycan fucosylation proved pervasive with 63% of the total and 89% of the complex-
type N-glycans containing this modification (Figure 4.5B). CD16a N-glycans also 
revealed a high degree of sialylation with 100% of the hybrid and 78% of the complex-










Table 4.1. NK cell donor information. 
 Donor 1 Donor 2 Donor 3 
Year of birth 1947 1951 1939 
Sex M M M 
ABO group A A A 
Rh(D) + - + 
CD16a allotype V/F V/V V/F 
Collection date 5/31/17 5/18/17 5/18/17 
NK cell count (106) 206 50 113 
NK cell viability 93% 83% 86% 
CD56+ in NK cell prep  83.8% 94.1% 95.6% 
Analysis of the individual glycoforms corresponding to the ten most intense N-
glycan species identified by MS showed complex type, core-fucosylated and sialylated 
biantennary N-glycans produced the two strongest signals in spectra of CD16a N-
glycans from all three donors (Figure 4.6). However, the next eight most intense ion 
species from each donor were predominantly hybrid forms (13/24) with comparable 
levels of complex-type (6) and oligomannose (5) forms including Man9 (2), Man 6 (2) 
and Man5 (1). This prevalence of N-glycan species with restricted processing in the 
three datasets is surprising given the reports of N-glycans from recombinant CD16a that 







Figure 4.4 (JTR). N-glycans identified from Donor 1 NK cell CD16a. The retention time from HILIC for the 
procainamide-derivatized N-glycans is plotted versus the exact mass. Insets for three N-glycans show MS 
identification. Cartoon diagrams show one possible configuration of the N-glycan species; isobaric 





Figure 4.5 (JTR). A comparison of CD16a N-glycan characteristics from different sources. A. The pie 
charts indicate what percentage of identified N-glycans fall into each of the three categories; extracted bar 
graphs show the breakdown of branching types for the complex-type N-glycans only. B. The percentage 
of each N-glycan species that contained at least one fucose residue. C. The percentage of each N-glycan 
species that contained at least one N-acetylneuraminic acid residue. 
 
N-glycan analysis of recombinant CD16a from HEK293 cells 
It is possible that CD16a N-glycans isolated from NK cells differ from 
recombinant CD16a N-glycans because the soluble recombinant fragment lacks the 
membrane anchor and experiences a different environment during secretion, or that NK 
cells produce a different mixture of glycan-modifying enzymes, or a combination of both 
possibilities. We expressed CD16a in HEK293F cells to assess the impact of the 
transmembrane and intracellular domains on N-glycan composition using two forms: 
soluble recombinant CD16a that contains the two extracellular antibody-binding 
domains (srCD16a) and full-length recombinant CD16a containing the complete CD16a 
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ORF, including the signal peptide, coexpressed with the Fc  receptor -chain 
(frCD16a). It is important to note that recombinant expression of frCD16a requires co-
expression with the Fc  receptor -chain or CD3 -chain to achieve cell-surface 
localization ((32) and data not shown). 
 Migration in SDS-PAGE of srCD16a (28-46 kDa) and frCD16a (38-43 kDa and 
47-59 kDa) showed much broader migration distributions than CD16a from NK cells 
(53-59 kDa), indicating a greater degree of heterogeneity for the recombinant forms 
(data not shown). We identified 122 and 86 individual procainamide-derivatized 
srCD16a and frCD16a N-glycans, respectively, with an average mass error of 0.0016 
Da (data not shown). Predominant N-glycans species from srCD16a and frCD16a were 
of a complex-type (82% and 73%, respectively) with low levels of oligomannose forms 
(5% and 9%, respectively) which stands in marked contrast to NK cell CD16a (Figure 
4.5). Furthermore, the complex types showed much greater representation of tri- and 
tetra-antennary forms than NK cell CD16a. Fucosylation of all srCD16a and frCD16a 
species was comparable (71%) and both were greater than NK cell CD16a (63%). 
Furthermore, fewer srCD16a and frCD16a N-glycans contained N-acetylneuraminic acid 
when compared to NK cell CD16a. This characterization of srCD16a is highly 
comparable to expressions in NS0 cells (19) with 6% oligomannose (Man4-6) or BHK 
cells with no oligomannose (33). 
 Closer inspection of N-glycan species revealed stark differences between the 
recombinant forms. The most intense N-glycan signals from srCD16a included a 
majority of complex-type forms (9/10) in contrast to frCD16a (6/10) that included a 
significant contribution from oligomannose forms (4/10; including Man9, Man8, Man7 
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and Man5; Figure 4.6). Furthermore, complex-type glycans from frCD16a showed a low 
level of hexose incorporation (2/6; likely galactose) in contrast to srCD16a with a very 
high degree of branching (7/9 w/3+ branches) and hexose incorporation (8/9). By these 
measures, the CD16a membrane anchor and Fc  receptor -chain co-expression 
resulted in the synthesis of a higher degree of hybrid and oligomannose N-glycans, but 
neither the soluble nor membrane-anchored recombinant CD16a forms recapitulated 
the N-glycan species found on NK cell CD16a.  It is important to note that by using a 
detergent to solubilize the cell membrane, folded but incompletely-processed CD16a 
residing in the ER and the Golgi at the moment of cell lysis will be purified in addition to 
CD16a from the cell surface. However, frCD16a was extracted using the same 
technique as NK cell CD16a, thus a direct comparison between these two sources is 
justifiable. Furthermore, the impact of incompletely-processed CD16a from the ER and 
Golgi cannot alone account for the increased prevalence of hybrid forms when 
compared to frCD16a or srCD16a because 100% of the NK cell CD16a hybrid 





Figure 4.6 (JTR). Possible N-glycan configurations corresponding to the most intense ions are shown 
from each CD16a source. Cartoon diagrams show one possible organization of the N-glycans; isobaric 
species were not distinguished. Values in the lower right corner of each cell indicate the relative ion 
intensities of these species, compared to the most abundant species from the same source. 
 
Oligomannose N-glycans increase receptor affinity 
The difference between CD16a N-glycan species from primary NK cells and 
recombinant expression systems appears compelling because both cell lineage and 
protein sequence impacted N-glycan remodeling. N-glycan composition can likewise 
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impact protein function, as is the case for IgG1, but it is unknown how composition 
affects the antibody-binding function of CD16a. To test whether N-glycan composition 
contributes to CD16a function, we expressed srCD16a in a HEK293S cell line that 
makes only oligomannose N-glycans with Man5 as the predominant species to compare 
binding to HEK293F-expressed srCD16a, characterized above, with predominantly 
complex-type and highly-branched N-glycans (Figures 4.5-4.6) (34). 
 
 
Figure 4.7 (GPS). CD16a N-glycan composition affect IgG1 Fc binding. Representative SPR sensograms 
for IgG1 Fc with an agalactosyl core fucosylated complex-type biantennary N-glycan (G0F) binding to 
recombinant CD16a with complex-type N-glycans (A) or oligomannose N-glycans (B). (C) A summary of 
dissociation constants for CD16a variants. Material was expressed either with HEK293F cells to 
synthesize primarily complex-type N-glycans (red bars) or with HEK293S cells to synthesize only 
oligomannose N-glycans (green bars). Values represent the average of at least two independent 




 CD16a with complex-type N-glycans bound IgG1 Fc in the G0F glycoform with a 
KD of 310 ±100 nM and 12-fold less affinity than CD16a with oligomannose N-glycans 
(25 ±17 nM; Figure 4.7). Furthermore, two of the five CD16a N-glycans previously 
identified as positive contributors to antibody binding, N45 and N162 (35-38), but not the 
remaining three N-glycans at positions 38, 74 and 169, were required for the enhanced 
antibody binding by CD16a displaying oligomannose N-glycans. Removing CD16a N-
glycans at positions 45 and 162 by N to Q mutations abolished enhancement from the 
oligomannose N-glycans. These data indicate that composition of the N45 and N162 
CD16a N-glycans impact function. 
 
NMR of different srCD16a N-glycoforms  
Our laboratory previously observed that different IgG1 Fc N-glycoforms led to 
different CD16a binding. These changes correlated with differences in crosspeak 
positions observed with solution nuclear magnetic resonance (NMR) spectroscopy and 
these differences reflected changes in secondary structure for one IgG1 Fc loop (39). 
We applied a similar approach and incorporated selective backbone 15N labels into Y, K 
and F residues to probe whether N-glycan composition affected 1H-15N heteronuclear 
single quantum coherence (HSQC) spectra of srCD16a. The 26 Y, F and K residues are 
evenly distributed throughout both CD16a extracellular domains. We expect changes in 
peak positions for these amino acid types will reflect CD16a structural changes in a 
manner analogous to characterizing ligand binding through a NMR crosspeaks that 
change position during a titration. Indeed, a spectrum of srCD16a expressed in 
HEK293S cells with oligomannose N-glycans showed different cross peak positions 
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than srCD16a with complex-type N-glycans (Figure 4.8). The largest deviations 
appeared in the center of the spectrum. We observed 24 peaks which is close to the 26 
expected, and of these, 8 showed different crosspeak positions in the two spectra with a 
combined 1H/15N chemical shift perturbation for each peak > 0.04 ppm  as calculated 
with Eq 2. Furthermore, one peak present in the spectrum of CD16a with complex-type 
N-glycans was absent in the spectrum of CD16a with oligomannose N-glycans and two 
peaks appeared in the spectrum of the oligomannose form. It is important to note that 
only two of the 26 labeled residues are within five amino acid residues, by primary 
sequence, from N-glycosylation sites indicating extensive regions of the protein are 
affected by N-glycan composition. This result is substantially different from hIgG1 Fc, 
where changes are limited to a single loop and not observed throughout the protein 
(39). 
 
Figure 4.8 (GPS). CD16a N-glycan composition impacts polypeptide structure. Select backbone amide 
crosspeaks observed in a HSQC experiment using CD16a expressed with either complex-type (red 
contours) or oligomannose (black contours) N-glycans. One peak present in the spectrum of CD16a with 
complex-type N-glycans but absent in the oligomannose form is indicated (†). Two peaks appearing in the 





A high percentage of oligomannose and hybrid structures, as well as biantennary 
forms constituting the largest subgroup of the complex-type species, characterize the 
CD16a N-glycans from primary human NK cells and indicate restricted processing 
compared to many serum proteins. This limited processing of NK cell CD16a N-glycans 
stands in stark contrast to N-glycans from recombinant CD16a with highly-modified and 
highly-branched carbohydrate structures. Furthermore, we provide clear evidence that 
N-glycan composition impacts antibody binding: CD16a modified with minimally 
processed oligomannose N-glycans bound IgG1 Fc with 12-fold greater affinity than 
CD16a with a mixture of highly-processed N-glycans. 
Recombinant CD16a is often used to characterize antibody binding affinity in 
many reports, including some of our own, due to practical considerations that include 
isolating sufficient material for in vitro studies. The differences in N-glycan composition 
from these different sources highlight the need to describe and develop the tools to 
mimic native source-specific composition in studies of receptor function. N-glycan 
composition is a neglected component of eukaryotic biology, particularly in the context 
of cell surface proteins, because access to primary materials is limited and the absolute 
mass of each specific receptor on a cell surface is very low (we estimate ~20-40 fg 
CD16a / NK cell). Furthermore, detailed studies linking N-glycan composition with 
function are challenging and likewise represent a barrier to a complete characterization 
of N-glycan roles in protein function. The characterization presented here provides a 
detailed description of these variables for CD16a from NK cells. N-glycosylation of 
109 
 
CD16a was targeted due to its relevance in mAb therapy but the other Fc  receptors 
are heavily glycosylated. This approach can be used to characterize N-glycosylation 
profiles of other Fc  receptors from primary human tissues.      
The relatively limited distribution of migration rates for NK cell CD16a in 
polyacrylamide gels and bias towards N-glycoforms with restricted processing was 
striking in comparison to frCD16a from HEK293F cells and indicates cell-type specific 
differences in N-glycan processing. Both frCD16a and NK cell CD16a were co-
expressed with a co-receptor that is required for localization to the cell surface. 
Differences in primary structure do not account for the observed differences in N-glycan 
processing: the CD16a polypeptide sequence and presence of the co-expressed Fc  
receptor -chain were the same in both NK cells and that used in HEK293F cells to 
express frCD16a. Cell-type specific differences in the glycosylation of a specific protein 
are known (40-44) and are justifiable given the complexity of gene expression and 
activity for glycan-processing enzymes in different tissues (45-50). 
Changes in receptor function resulting from limited N-glycan processing were 
mirrored by changes in a 2d spectrum of [15N-Lys/Tyr/Phe]-labeled CD16a (Figures 
4.7-4.8). The magnitude of peak shifts and the extent of peaks experiencing shifts in 
CD16a are comparable to analyses of proteins that experience a conformational 
rearrangement upon ligand binding. In the latter example, ligand docking stabilizes a 
specific protein conformation. Surprisingly, CD16a N-glycan composition imposed a 
similar conformational adjustment that was experienced by a large number of backbone 
amides, indicating that specific features of the N-glycans interact with residues on the 
polypeptide surface. Our group recently described the formation of intramolecular 
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interactions between the polypeptide and N-glycans at N45 and N162 (38). N-glycans at 
these positions likely differentially impact protein conformation, based on N-glycan 
composition at each site. Thus, the CD16a N-glycans do not behave as largely inert 
modifications, but rather interact with polypeptide residues to modulate protein function. 
The IgG1 Fc N-glycan composition also impacts receptor binding through intramolecular 
interactions (15,39,51,52). 
Numerous prior studies focused on the modulation of CD16a affinity by IgG N-
glycan composition. This wealth of information on IgG N-glycosylation is due primarily to 
the availability of IgG; here we focused on the effect of CD16a N-glycosylation on 
antibody binding. The observation that CD16a N-glycosylation affects binding affinity, 
potentially to a greater extent than IgG, makes CD16a N-glycosylation an important 
aspect of immune system function with the potential for clinical implications. There are 
two important limitations to the present study: 1) the restricted donor demographic 
variability could mask potential N-glycan composition variability present in the larger 
population and 2) it is currently unclear if changes to CD16a N-glycan composition that 
increase antibody binding in SPR experiments enhance NK cell response. Moreover, 
CD16a-expressing cells, including NK cells, are involved with multiple pathologies (53-
56). Therefore, this information regarding specific NK cell N-glycans on CD16a can be 
applied to probe the connection between patient-specific changes in autoimmune 







All materials purchased from Sigma-Aldrich unless noted.  
 
Cell isolation  
NK cells were isolated from leukocyte reduction filters (LRS filters) obtained from 
LifeServe (Ames, IA) and DeGowin Blood Centers (Iowa City, IA) after the 
plateletpheresis procedure. Donors signed consent forms permitting the use of donated 
blood products for research purposes. We do not directly enroll donors because we 
obtain materials from the LifeServe and DeGowin Blood centers. Cell isolation 
procedures were performed within 3 h of the time the donor completed the apheresis 
procedure. NK cells were isolated by negative selection using the RosetteSep 
Enrichment Cocktail following the recommended protocol (Stem Cell Tech.) with the 
following minor changes: LRS filters were drained into a sterile 50 mL tube and the 
contents diluted to 30 mL using PBS with 2% IgG-depleted FBS. The cell suspension 
was then split into 2 x15 mL aliquots and each mixed with 750 µl of the negative 
selection cocktail. After a 20 min incubation, the steps mentioned in the protocol were 
followed. Contaminating erythrocytes were then removed by incubating the cells with 
erythrocyte lysis buffer (155 mM ammonium chloride, 12 mM sodium bicarbonate, and 
0.1 mM ethylenediamenetetraacetic acid, pH 7.4) for 10 min at RT. Finally, cells were 
counted and viability analyzed with trypan blue, then frozen at -80 °C. CD16a allotype 
was determined by sequencing cDNA corresponding to CD16a (cDNA isolation 





NK cells were first blocked with 5 µg hIgG1 (Athens Research and Technology) 
before incubation with primary antibodies. For each flow cytometry experiment, 5 x 105 
NK cells were stained with primary antibody for 40 min in dark on ice, including 2 µg/mL 
mIgG2a anti-hCD56 (MEM-188, BioLegend) and 2 µg/mL mIgG1 anti-hCD16 (3G8) or 
isotype controls, mIgG1 (Research and Diagnostics Systems) and mIgG2a 
(BioLegend). The cells were washed with 2 x 2 mL phosphate buffered saline, 0.05% 
sodium azide by centrifuging at 600 xg for 8 min and removing the supernatant after 
each centrifugation. Fluorophore-conjugated secondary antibodies were added 
including anti mIgG1-APC (RMG1-1, BioLegend) and anti mIgG2a-PE (RMG2a-62, 
BioLegend) and incubated on ice for 40 min. Cells were fixed in 1% paraformaldehyde 
before loading them onto a BD FACSCanto (BD Biosciences). For cell purity 
assessment, NK cells were gated in the side and forward scatter plot to exclude cell 
debris and cells (primarily erythrocytes) smaller than lymphocytes. Gating of double 
stained cells was determined by comparing to the fluorescence intensity of the negative 
(no primary) control. Isotype controls consistently showed no positive staining for either 
primary antibody for the first 15 NK cell isolations performed from donors of both gender 
and a wide age range.  
 
Anti-hCD16 expression and purification 
Open reading frames encoding the anti-hCD16 mouse IgG1 (3G8) heavy and 
light chains were synthesized (IDT). The heavy chain sequence was cloned into 
pGEef1Puro vector (provided by Dr. Kelley Moremen, University of Georgia) using the 
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Gateway cloning system (Life Tech). The flanking attB sites for gateway cloning of 
heavy chain were included in the synthesized heavy chain gene. The transfer of gene to 
final pGEef1Puro vector was performed in a two-step gateway reaction following 
manufacture’s protocol with pDONR221 (Life Tech) as the intermediate vector. The light 
chain sequence was cloned into the pGEN2 vector using the NotI and HindIII restriction 
sites (57). 
3G8 monoclonal antibody was generated by co-transfecting HEK293F cells with 
3 g/mL pGEef1Puro:(heavy chain) and 1.5 g/mL pGEN2:(light chain) as described 
(57). Antibody was secreted into the medium, adsorbed to a protein-A Sepharose fast 
flow resin (GE Life Sciences) and eluted with 100 mM glycine, pH 3.0 followed by 
immediate neutralization with 33 % 1 M Tris, pH 8.0. Purified antibody was washed to 
replace the buffer with a buffer containing 25 mM MOPS, 100 mM sodium chloride, 
pH.7.2 and then coupled to AminoLink aldehyde-functionalized agarose beads at 1 
mg/mL of resin according to the product protocol (Thermo Scientific).  
Antibody used to immunoprecipitate CD16a for N-glycan analysis differed in two 
important ways. First, the mouse IgG1 Fc region was replaced with human IgG1 Fc. 
Second, this chimeric antibody was treated with EndoS to remove the Fc N-glycan; 3G8 
contains no N-glycosylation sequon in the Fab domains. EndoS was expressed in E. 
coli using a deposited plasmid and purified as described (AddGene). EndoS was 
incubated with 3G8 in 20 mM MOPS, 100 mM NaCl, pH 7.2, at a 1:50 (EndoS:3G8) 
molar ratio for 18 h at RT. The digestion was assessed by resolving the protein with 
SDS-PAGE and staining with coomassie blue. Glutathione beads were incubated with 
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3G8 and GST-EndoS to remove the GST-EndoS before coupling antibody to agarose 
beads. 
 
Recombinant CD16a expression 
The soluble extracellular fragment of CD16a (srCD16a) was prepared as a 
recombinant GFP-fusion protein and cleaved with TEV as previously described using 
HEK293F cells (15). Open reading frames encoding the full-length recombinant CD16a 
protein (frCD16a) and the Fc  receptor subunit  (-chain) were cloned from cDNA 
obtained from NK cells and monocytes, respectively. Total RNA was isolated from 
10x106 monocytes (prepared with negative selection, Stem Cell Tech) and 5x106 NK 
cells using the Trizol reagent following the manufacturer’s protocol (ThermoFisher). A 
high capacity RNA to cDNA kit (Applied Biosystems) was used to reverse transcribe 
500 ng RNA from each cell type and amplified with AccuPrime Pfx DNA polymerase 
(Life Tech) to generate full length cDNA. Primers pairs for frCD16a were:  5'-
cagcggccgccCAGTGTGGCATCATGTGGCAG and 5'- 
ggatccaagcttTTTGTCTTGAGGGTCCTTTCT containing NotI and HindIII sites, 
respectively. Similarly, two primers 5'-gaattcCTCCAGCCCAAGATGATTCCAG and 5'-
ggatcctcaCTACTGTGGTGGTTTCTCATGC with EcoRI and BamHI sites, respectively, 
were used to amplify gene for -chain. Primers were designed to include the native 
signal sequence form both genes. Both PCR fragments were cloned into pGEM-T Easy 
vectors following the manufacturer’s guidelines (Promega). Full-length CD16a was sub-
cloned into pGEN2 vector using the NotI and HindIII restriction sites. The -chain was 
sub-cloned into pGEef1Puro vector using the EcoRI and BamHI restriction sites. 
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pGEN2-frCD16a and pGEef1Puro-γ-chain vector were co-transfected in a 1:2 mass 
ratio in HEK293F cell line as described (57). HEK cells were transfected at a density of 
3.0 x106 cells mL-1 with a viability >96%. Expressions usually proceeded for 5 d or until 
cell viability fell below 50%. Typical yields for srCD16a were 0.2 mg protein mL-1 culture 
medium. Cell surface expression of CD16a in HEK293F cells was confirmed by flow 




These methods were adapted from a previously published protocol to achieve a 
preparative scale purification (58). NK cell or HEK293F cells expressing full-length 
CD16a were lysed by resuspending the frozen pellet in ice-cold lysis buffer (100 mM 
Tris, 100 mM sodium chloride, 5 mM ethylenediamenetetraacetic acid, 5 mM oxidized 
glutathione, 10 µM potassium ferricyanide, 1 mM 4-(2-aminoethyl)benzenesulfonyl 
fluoride, 10 mg/mL dodecylmaltoside, pH 8.0) with 200 µL added for every 1x107 cells 
by repeated pipetting, followed by a 20 min incubation on ice. Cell debris was removed 
by centrifugation at 10,000 xg for 10 min at 4 °C. Supernatant was incubated for 1 hr. at 
4 °C on a rocker with 5 µL protein G sepharose (Sigma Aldrich) per 200 µl lysate. 
Protein G sepharose was removed by centrifuging the lysate at 500 xg for 5 min. The 
recovered supernatant was sonicated in a bath sonicator for 1 min, followed by freezing 
at -80 °C and slowly thawed on ice. 3G8-coupled agarose beads (20 µL) were added 
per 200 µL NK cell lysate and incubated for 1 h at 4 °C on a rocking shaker. The resin 
was centrifuged at 500 xg for 5 min and washed twice with lysis buffer using 10x the 
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resin volume for each wash followed by two washes with 50 mM Tris, 100 mM sodium 
chloride, pH 8.0 and final two washes with 100 mM ammonium carbonate, pH 8.0. 
CD16 was eluted in 45:55:0.1 (HOH:acetonitrile:TFA) by centrifugation through a spin 
column to retain the resin.  
 
PNGase F digestion of CD16a 
PNGase F digestion of CD16a isolated from NK cells was performed per 
manufacturer’s protocol. NK cell CD16a bound to 3G8-agarose was boiled at 100 °C for 
10 min in 1x denaturing buffer (0.5% sodium dodecylsulphate, 40 mM dithiothreitol) 
followed by addition of GlycoBuffer2 and 10% NP-40 to the reaction (New England 
Biolabs). After adding 1 µL PNGase F, the sample was incubated at 37 °C for 4 h. and 
the reaction was stopped by heating at 95 °C for 5 min after the addition of 1 volume 2x 
SDS-PAGE sample buffer containing 10% beta-mercaptoethanol. A control reaction 




Eluted protein was resolved on a sodium dodecyl sulfate polyacrylamide gel 
(12% unless mentioned otherwise) and transferred onto a Polyvinylidene difluoride 
(PVDF) membrane using the one-step electroblotting system (ThermoFisher). The 
membrane was blocked with 5% dry milk in TBS Tween-20 (TBST) buffer for 1 h. at RT. 
All incubations and washes were performed on an orbital shaker. Following blocking, 
the membrane was stained for 18 h at 4 °C with anti-hCD16 (Research and Diagnostic 
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Systems, 0.1 µg/ml) in 5% milk in TBST buffer. The blot was washed 4x with TBST 
buffer for 5 min and stained with secondary anti-goat-HRP (Research and Diagnostic 
Systems, dilution 1:2000) in 5% milk in TBST buffer for 1 h at RT. After 4x washing the 
blot was imaged on a ChemiDoc XRS+ Image system (BioRad) using the ECL Western 
Blotting Substrate (ThermoFisher).  
 
Peptide mass spectrometry 
CD16 for peptide sequencing was isolated as described in the 
immunoprecipitation protocol. In the first instance, CD16a was excised from 12% SDS-
PAGE at the same size as detected by the western blot detection system. The gel was 
subjected to standard in-gel trypsin digest on the Molecular Dynamics ProGest 
(Genomic Solutions) instrument. The sample was then dried down and resuspended in 
1.25 µL buffer B (0.1% formic acid in acetonitrile). In the second instance, peptides 
retained by the C18 sep-pak during the isolation of N-glycans from donor 3 (following 
treatment with PNGaseF and trypsin) were eluted with isopropanol and lyophilized. Both 
samples were resuspdended in 23.75 µL buffer A (0.1% formic acid in water) was 
added to the sample, mixed, spun down and put in a sample vial. The vial was then 
loaded onto a Q-Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo 
Scientific) equipped with an 1260 HPLC (Agilent) and C18 column and eluted as 
described (59). Peaks from MS1 and MS2 spectra were searched with the mammalian 
Mascot database server. Raw data were processed with Sequest HT (v 1.17) and 
Mascot 2.2.07 (Matrix Science). The peptides identified were then analyzed using 




Procainamide labeling of PNGase F-released N-glycans 
 Following heat denaturation of CD16a for 5 min at 90 °C, 1 µL sequencing grade 
trypsin (Promega; 1 mg/mL in 50 mM ammonium carbonate, pH 8.0) was added and 
incubated at 37 °C for 18 h after mixing. The trypsinized sample was again incubated at 
90 °C for 5 min to denature the trypsin, followed by cooling for 5 min on ice. PNGase F 
(1 µL; glycerol-free; New England BioLabs) was then added to the sample and incubated 
at 37 °C for 18 h. A Hypersep C18 column (ThermoFisher) was washed 3x1 mL of 
methanol then 3x1 mL 5% acetic acid. Free N-glycans were isolated by applying the 
sample, diluted in 5% acetic acid, over the C18 column and collecting the flow through. 
Wash fractions (3x1 mL) of 5% acetic acid were collected in the same tube, then frozen 
and lyophilized. The lyophilized sample was then resuspended in 200 µL of double-
distilled water by vortexing and transferred to a microcentrifuge tube, frozen and 
lyophilized again. The sample was then resuspended in 10 µL of water. A stock solution 
containing 2 M sodium cyanoborohydride, 1 M procainamide and 50% acetic acid (10 µL) 
was added to the sample, mixed and incubated for 18 h at 37 °C. The sample was then 
lyophilized and resuspended into 10 µL of double-distilled water. 
 
Hydrophilic interacting chromatography mass spectrometry 
The HPLC instrument used was an Agilent 1260 HPLC with an Acquity UPLC 
Glycoprotein BEH Amide, 300 Å, 1.7 µm Hydrophilic Interaction Liquid Chromatography 
(HILIC) column (Waters). The lyophilized procainamide-labeled glycan samples were 
resuspended in double-distilled water and 9 µL was injected onto the column 
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prewashed with 25% Solvent A (0.1% formic acid and 0.01% TFA in double-distilled 
water) and 75% Solvent B (0.1% formic acid and 0.01% TFA in acetonitrile) with a flow 
rate of 0.1 mL/min. The glycans were then eluted by a gradient at 0.1 mL/min flow rate 
unless otherwise indicated; 0.5-10.5 minutes (gradient from 25%-35% A), 10.5-40.5 
minutes (a gradient from to 35% to 50% A), 40.5-41.5 minutes (50% to 100% A), 41.5-
43.5 minutes (100% A), 46.5-47 minutes (25% A, 75% B) at 0.05 mL/min and 47-60 
minutes (25% A, 75% B) at 0.1 mL/min at 45 °C. Upon elution, the samples were 
coupled in-line to a Q Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer 
(Thermo Scientific). The mass spectrometer (scan range 266.7- 4000 m/z) subjected 
ions to HCD fragmentation (scan range of 200-2000 m/z) at a normalized collisional 
energy of 27 eV. In between samples, identical chromatography and MS analyses were 
performed following an injection of water. These were scanned to ensure no carryover 
between samples. Sample spectra were then analyzed by converting the RAW spectra 
file to text format with MSConvert. The output was then scanned against a list of N-
glycans calculated for singly, doubly and triply charged, procainamide-derivatized 
species to identify peaks with corresponding retention times and intensities. These 
matches were then validated manually by analyzing the RAW file in XCaliber (Thermo 
Scientific). Average mass error for each data set was calculated according to equation 
1. 
 










IgG1 Fc binding assays by SPR 
Expression, purification and preparation of IgG1 Fc in the G0F glycoform and 
CD16a binding analyses by surface plasmon resonance were performed as described 




Isotope-labeled srCD16a expression and NMR experiments were conducted as 
described (39). Chemical shift perturbations (CSP) were calculated using equation 2. 
𝐶𝑆𝑃 = √(𝛿 𝐻1 )2 +
1
6
(𝛿 𝑁15 )2   Eq. 2 
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CHAPTER 5. GENERAL CONCLUSION 
 
 The interaction between IgG1 and FcRs is modulated by N-glycosylation 
composition. CD16a and CD16b are nearly identical FcRs which bind to IgG1 with 
different affinities. The role of a single amino acid residue, G129 in CD16a or D129 in 
CD16a, was explained to be the major difference in binding between these two 
receptors using SPR. Furthermore, the first crystal structure of glycosylated CD16b in 
complex with IgG1 Fc provided important structural information which explain the 
energetic penalty of residue D129 in CD16b as compared to G129 in CD16a. CD16 with 
G129 was also described to have enhanced affinity for IgG1 when expressing Man5 N-
glycans on the surface rather than complex-type. These studies may provide essential 
information which help optimization of mAb therapies for the purposes of selectively 
targeting CD16a or CD16b. 
 Endogenous FcR N-glycosylation was previously undiscovered before this work. 
Our previous in vitro studies indicate CD16a N-glycan composition affects binding to 
IgG1, thus it was important to understand what compositions are found in vivo. These 
studies indicate CD16a and CD32a N-glycosylation from monocytes vary by site, donor 
and cell type. The current population size is quite limited at this point, but methods 
developed can now be applied to a larger population size to understand N-glycan 
processing differences from individuals who vary by gender, age, and disease states.  
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APPENDIX A. A RARE ALLOTYPE ON CD16A FROM MONOCYTES ISOLATED 
FROM PLATELET APHERESIS DONORS AFFECT N-GLYCOSYLATION 
COMPOSITION AT SITE N45 
 
Introduction 
 CD16a is predominantly expressed on NK cells and a subset of monocytes. 
CD16a is the main receptor for antibody dependent cellular cytotoxicity (ADCC) in NK 
cells and nonclassical (CD14++, CD16+) monocytes (1). CD16a is N-glycosylated at 
five N-glycosylation sites; N38, N45, N74, N162 and N169. CD16a N-glycosylation and 
polymorphisms have been described to affect binding to IgG antibodies (2-3). Two main 
polymorphisms exist on CD16a which dictate binding and function; L/H/R48 and 
V/F158. Single copy allele frequencies for residue 48 are estimated to be 84% L48, 8% 
H48 and 6% R48 (7). Rare homozygous individuals for the H48 allele suffer from severe 
recurrent herpes virus infections as well as frequent upper respiratory infections (4-8). 
Interestingly, NK cell ADCC was unaffected but H48-encoding homozygotes did have 
compromised natural cytotoxicity (4-5). This finding suggests the H48 polymorphism 
does not affect IgG binding to CD16a unlike the V/F158 polymorphism. CD16a V158 is 
associated with higher binding to antibody than the F158 allele and in vivo V158 
homozygous individuals respond better to mAb therapies presumably because of this 
higher affinity (9-10). The CD16a H48 allele is described to abrogate the interaction 
between CD16a and CD2 shown through immunoprecipitation and confocal microscopy 
co-localization experiments implicating CD16a function as a co-stimulatory receptor for 
natural cytotoxicity along with its canonical role in ADCC (11). Patients homozygous for 
H48 in this study were described to have decreased CD2 expression as well. CD16a 
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H48 has been relatively well studied in the context of NK cells but has not been studied 
in the context of nonclassical monocytes nor has the role of N-glycosylation of CD16a 
from individuals with the H48 allele been elucidated before. CD16a N-glycosylation has 
recently been characterized from primary tissue including monocytes (Chapter 3) and 
NK cells (12). In this study, N-glycosylation compositions are compared between two 
allele-specific CD16a N45 N-glycopeptides containing the L48 or H48 residue from 
human monocytes. 
Results 
The CD16a allotype H48 causes different N-glycosylation processing in 
monocytes at site N45 as compared to L48. The CD16a H48 specific allele was found 
on the N45 glycopeptide in the dataset including a pool of 3 donors (MoB) as described 
in Chapter 3. MS2 fragmentation confirmed these allele specific glycopeptides. The 
diagnostic peptide + GlcNac ion was observed for the L48 (Figure A.1A) and H48 
alleles (Figure A.1D-E). These peptides are the product of a missed Glu-C cleavage 
site while the fully cleaved product is displayed in Figure A.1B and A.1C. MoB had a 
single donor, Mo06iii, which was confirmed by DNA sequencing to be heterozygous for 
both the V/F158 and L/H48 alleles (Figure 3.1F) (Chapter 3). The relative intensities for 
all monocyte donors with the L48 glycopeptide (peptide 2) and the H48 glycopeptides 
were analyzed for site N45 (Figure A.2). The 10 most abundant N-glycans from all 
monocytes at site N45 from peptide 2 are summarized in Figure A.2A for the L48 allele. 
These data are from the same donors analyzed in Chapter 3. Six N-glycans identified 
on the CD16a N45 L48 glycopeptide were hybrid type while there were two complex 
and two oligomannose type in the 10 most intense glycopeptides. Percent composition 
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of the top 10 N-glycans from peptide 2 was 68% hybrid, 23% complex and 9% 
oligomannose-type N-glycans. Figure A.2B displays the top 10 most abundant N-
glycans identified from the CD16a N45 H48-specific glycopeptide. Interestingly, there 
were 5 hybrid, 5 complex and no oligomannose types identified and percent 
composition was 62% hybrid and 38% complex-type suggesting greater processing of 
the N45 N-glycan when H48 is present. 
 
Figure A.1. MS2 fragmentation and DNA sequencing confirms L/H48 specific glycopeptides from a 
monocyte donor pool. A) CD16a N45 L48 allele-specific hybrid-type glycoepeptide is a missed Glu-C 
cleavage site product. B-C) CD16a N45 oligomannose and hybrid type glycopeptides with Glu-C 
cleavage does not allow the L/H allele peptide to be distinguished. D-E) CD16a N45 H48 allele-specific 
hybrid-type glycopeptides are missed Glu-C cleavage site products. F) Sanger sequencing confirms this 
donor to be heterozygous for V/F158 and L/H48 alleles. A-E) Oxonium ions for mono, di and 
trisaccharides are identified and labeled appropriately. The peptide + GlcNac peak is labeled 




Figure A.2. The top 10 N-glycans identified on CD16a N45 is shifted to more highly processed, complex-
types in glycopeptides containing the H48 allotype as compared to L48. A) The top 10 N45 glycopeptides 
identified on the L48 allele specific glycopeptide from all monocyte donors includes 6 hybrid, 2 complex 
and 2 oligomannose type N-glycans based on relative intensity. Percent composition of each type breaks 
down to 68% hybrid, 23% complex and 9% oligomannose type. B)  The top 10 N45 glycopeptides 
identified on the H48 allele specific glycopeptide include 5 hybrid and 5 complex-type N-glycans based on 
relative intensity. Percent composition of each type breaks down to 62% hybrid and 38% complex-type. 
A-B) The glycopeptide red N is N45 while the L/H48 residue is labeled cyan in the N45 glycopeptide 
identified. Relative abundance is based on relative intensities. 
 
Discussion 
CD16a H48 displays more processed, complex-type N-glycans than CD16a L48 
from monocytes at site N45. Hybrid and oligomannose-type N-glycans total 77% and 
23% for complex-type on the L48 specific glycopeptide at N45 while the H48 specific 
glycopeptide at N45 displays 62% hybrid and 38% complex-type. Furthermore, two 
tetraantennerary complex-types are in the top 10 of the H48 specific glycopeptide 
indicating highly processed forms not seen for L48. Interestingly, CD16a isolated from 
an NK cell donor heterozygous for H/L48 also displayed similar increased processing at 
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the CD16a H48 specific N45 glycopeptide as compared to L48 (data not shown, 12). 
Additionally, this difference in N-glycosylation was only observed on the N45 glycosite. 
This is likely because the L/H48 residue resides near the N45 loop thus it is likely this 
residue can affect loop dynamics affecting the N45 N-glycan mobility. Increased mobility 
of the N-glycan would likely make the N-glycan more accessible to glycosyl transferases 
allowing more processing of the N-glycan. However, more studies on the role of L/H48 
concerning N-glycan mobility and processing need to be performed to fully understand 
the effect of H48. The shift in CD16a N-glycosylation processing at N45 from monocytes 
and NK cells may be a modest one, however this data adds to the molecular 
characterization of the disease states in homozygous individuals for the H48 allele (4-5). 
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APPENDIX B. INTRADOMAIN INTERACTIONS IN AN NMDA RECEPTOR 
FRAGMENT MEDIATE N-GLYCAN PROCESSING AND CONFORMATIONAL 
SAMPLING 
 
A manuscript in Structure. Doi: 10.1016/j.str.2018.09.010 
 
The following sections are the contributions by JTR to the manuscript cited above. 
 
Introduction 
The N-methyl-D-aspartate receptor (NMDAR) is an important ionotropic 
glutamate receptor which is a ligand-gated ion channel and essential to synaptic 
transmission in the central nervous system (1-3). Neurotransmitter receptors like 
NMDAR have been described to be important in learning, memory, development and 
synaptic plasticity (4-6). NMDARs are integral membrane heterotetramers made up of 2 
GluN1 subunits and 2 GluN2 (A-D) or GluN3(A/B) subunits (7-9). Each of these 
subunits contain a ligand binding domain (LBD), transmembrane domain, intracellular 
C-terminal domain and amino-terminal domain (ATD). The GluN1 subunit is heavily 
glycosylated with up to 11 N-glycosylation sites in the extracellular domain (10-12). N-
glycosylation sequons are highly conserved amongst NMDARs and are expected to be 
functionally important. Indeed, N-glycosylation is essential for proper oligomerization 
(14, 15) and has been described to stabilize glycine binding (16, 17)). NMDAR N-
glycosylation of recombinantly expressed material has not been identified. This study 
identifies the N-glycosylation profile of the GluN1-LBD domain expressed in HEK293f 
cells. Other studies that are part of the published manuscript not discussed here use an 
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approach encompassing NMR, MD and MS methods to correlate N-glycosylation site-
specific processing of GluN1-LBD to intramolecular carbohydrate/polypeptide contacts 
and protein structure. 
Experimental Procedures 
Procainamide labeling of PNGase F-released N-glycans  
Following heat denaturation of 50 μg recombinant GluN1 LBD for 5 min at 90 °C, 
1 µL sequencing grade trypsin (Promega; 1 mg/mL in 50 mM ammonium carbonate, pH 
8.0) was added and incubated at 37 °C for 18 h after mixing. The trypsinized sample 
was again incubated at 90 °C for 5 min to denature the trypsin, followed by cooling for 5 
min on ice. PNGase F (1 µL; glycerol-free; New England BioLabs) was then added to 
the sample and incubated at 37 °C for 18 h. A Hypersep C18 column (ThermoFisher) 
was washed with 3 × 1 mL methanol then 3 × 1 mL 5% acetic acid. Free N-glycans 
were isolated by applying the sample, diluted in 5% acetic acid, over the C18 column 
and collecting the flow through. Wash fractions (3 × 1 mL 5% acetic acid were collected 
in the same tube, then frozen and lyophilized. The lyophilized sample was resuspended 
in 200 µL ddH2O by vortexing and then transferred to a microcentrifuge tube, frozen, 
and lyophilized. The sample was then resuspended in 10 µL of ddH2O. A stock solution 
containing 2 M sodium cyanoborohydride, 1 M procainamide and 50% acetic acid (10 
µL) was added to the sample, mixed and incubated for 18 h at 37 °C. The sample was 





Hydrophilic interacting chromatography mass spectrometry 
The HPLC instrument used was an Agilent 1260 HPLC with an Acquity UPLC 
Glycoprotein BEH Amide, 300 Å, 1.7 µm Hydrophilic Interaction Liquid Chromatography 
(HILIC) column (Waters). The lyophilized procainamide-labeled glycan samples were 
re-suspended in ddH2O and were injected (3 µL; corresponding to 15 μg of GluN1 LBD) 
onto the column prewashed with 25% Solvent A (0.1% formic acid and 0.01% 
trifluoracetic acid in ddH2O) and 75% Solvent B (0.1% formic acid and 0.01% 
trifluoracetic acid in acetonitrile) at 0.1 mL/min. The glycans were then eluted by a 
gradient at 0.1 mL/min flow rate unless indicated otherwise; 0.5-10.5 minutes (gradient 
from 25%-35% A), 10.5-40.5 minutes (a gradient from to 35% to 50% A), 40.5-41.5 
minutes (gradient to 100% A), 41.5-43.5 minutes (100% A), 46.5-47 minutes (25% A, 
75% B) at 0.05 mL/min and 47-60 minutes (25% A, 75% B) at 0.1 mL/min at 45 °C. 
Upon elution, the samples were coupled in-line to a Q Exactive Hybrid Quadrupole-
Orbitrap Mass Spectrometer (Thermo Scientific). The mass spectrometer (scan range 
266.7- 4000 m/z) subjected ions to HCD fragmentation (scan range of 200-2000 m/z) at 
a normalized collisional energy of 27 eV. In between samples, identical chromatography 
and MS analyses were performed following an injection of water to ensure no carryover 
between samples. Samples spectra were then analyzed by running the software Byonic 
(Protein Metrics) from the RAW spectra file. These matches were then validated 
manually by analyzing the RAW file in XCaliber (Thermo Scientific). Average mass error 









       Eq. 1 
Results 
Glycomics of the recombinant GluN1 LBD 
Glycan remodeling may provide additional insight into N-glycan/polypeptide 
interactions. The predominant GluN1 glycoforms are expected to be of an 
oligomannose-type (13,14) however, it is unclear if the factors that restrict N-glycan 
processing in neuronal cells will be present when expressing the isolated GluN1 LBD 
with HEK 293F cells. It is noteworthy that the N-glycan NMR peaks observed using the 
GluN1 LBD expressed from HEK293F cells (with the capacity to generate highly-
processed complex-type N-glycans) were comparable to the same peaks from the 
GluN1 LBD expressed from HEK293S (lec1-/-) cells (that expresses protein with 
primarily Man5 N-glycans;). This comparability indicates that N-glycan composition 
minimally impacted the chemical environment for these 1H-13C correlations. To study 
the global N-glycan composition in the recombinant GluN1 LBD expressed with the 
HEK293F cell line, N-glycans were released by PNGase F treatment and derivatized 
using procainamide for mass spectrometric analyses. We identified 52 unique N-glycan 
species that classified into 1.9% hybrid, 13.5% oligomannose and 84.6% complex types 
with an average mass error between the calculated mass and observed mass was 
0.007 Da (Figure B.1A). Thus, the N-glycans found on the GluN1 LBD expressed in 
HEK293F cells are different from those expected on neuronal NMDARs. This presents 
an alternative opportunity to probe intramolecular N-glycan interactions by assessing 
the extent of N-glycan remodeling. For example, the complete absence of terminal sialic 
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acid modifications potentially indicates interactions between non-reducing terminal 
carbohydrate residues that prevent sialic acid addition in a cell line that is capable of 
heavily sialylating N-glycans (19,20). 
The subset of complex-type glycans were further characterized to reveal 
biantennary (32%), triantennary (32%) and tetraantennary or greater (36%) forms 
(Figure B.1A). Fucose was found attached to 65.9% of complex, 100% of hybrid and 
14.3% of oligomannose types (Figure B.1B). N-acetylneuraminic acid (a sialic acid) 
modified 70.5% of complex type, 0% of oligomannose and 0% of hybrid glycoforms. 
These data identify a distribution of N-glycan composition and the presence of a 
majority of highly processed glycoforms. Therefore, the N-glycans in the recombinant 
GluN1 fragment are exposed to glycan modifying enzymes in the ER and Golgi and 
factors restricted to the expressed fragment do not limit N-glycan processing to the 
oligomannose forms identified on the GluN1 subunit from native tissue (13). 
 
Figure B.1. Procainamide-derivatized free N-glycan composition of recombinant GluN1-NMDA expressed 
from HEK293F cells (JTR). A) Relative abundance of the N-glycans identified are characterized as hybrid, 
oligomannose and complex. Complex-type is further split into bi, tri and tetra+ antennary complex N-





Mass Spectrometry of N-glycans, molecular dynamics (MD) simulations and 
NMR correlated N-glycan composition with polypeptide-carbohydrate interactions. A 
recently developed NMR 2d one-bond proton (1H) and carbon (13C) correlation 
experiment was used to identify these contacts. Here we defined the N-glycan 
composition of recombinant GluN1-NMDAR using glycomics. Furthermore, 
glycoproteomics showed differential processing depending on N-glycosylation site. 
Interestingly, MD simulations observed intramolecular contacts of the carbohydrates 
and polypeptide which help explain differences in GluN1-NMDAR site-specific N-
glycosylation processing. These intramolecular contacts within GluN1-NMDAR were 
hypothesized to limit processing by glycan modifying enzymes. 
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